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CHAPTER 1
INTRODUCTION
1.1 Epidermal Growth Factor Receptor (EGFR)
A. Discovery and Structure
In 1962 Stanley Cohen reported the isolation of the factor responsible for early
development of the incisors and eyelids of mice. He proposed that secretions from the
salivary gland contained the growth promoting factor, which he termed epidermal growth
factor (EGF) (Cohen, 1962; Schlessinger, 2000). His work began the investigation of
EGF and the search for its receptor.

Membranes prepared from A-431, human

epidermoid carcinoma cells, incubated with

125

I-EGF resulted in the binding of EGF to

the 150 kDa epidermal growth factor receptor (EGFR). It was later discovered that EGF
binding to EGFR resulted in phosphorylation of the membranes (Carpenter, 1979).
Because the EGF-dependent kinase activity and the substrates for phosphorylation copurified with EGFR Cohen noted that EGF-induced kinase activity could be an entity of
the receptor (King et al., 1980). EGFR was the first identified receptor tyrosine kinase
(RTK). RTKs are a category of transmembrane proteins that undergo ligand-dependent
conformational changes in the presence of extracellular ligands. This results in the
activation of an intracellular domain with the ability to catalyze the enzymatic transfer of
a -phosphate from ATP to tyrosine residues in protein substrates. EGFR is the model by
which most RTK-induced cellular processes in eukaryotes are studied (Schlessinger,
2000).
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In 1984 Ullrich et. al. cloned and sequenced the complete human EGFR precursor
from A-431 cells, which revealed direct homology to the avian erythroblastosis virus
(AEV) v-erbB oncogene (Ullrich et al., 1984). The v-erbB oncogene is located on
chromosome 7p11-13 and spans 110kbp of DNA. The gene contains 26 exons and
transcribes a gene that translates into a 1210 amino acid (AA) precursor protein that
undergoes cleavage resulting in a mature 1186 AA protein. There are 12 possible Nlinked glycosylation sites accounting for 20% of the 170 kDa protein’s molecular weight
(Jorissen et al., 2003).
EGFR is one member of the ErbB family (ErbB2, ErbB3, ErbB4) of RTKs.
Through structural analysis, EGFR, like each of its family members, was found to have
four primary domains: a putative signal sequence (24AA), an extracellular domain (621
AA), a transmembrane domain (23AA), and a cytoplasmic domain (542AA) (Ullrich et
al., 1984). The signal sequence directs the post-translational transport of EGFR to the
cell surface, but is cleaved off resulting in the mature from of EGFR. The extracellular
domain of EGFR, and each of the ErbB family members, contains four sub-domains (I,
II, III, IV) (Garrett et al., 2002; Ogiso et al., 2002). Activation of ErbB receptors is
initiated by the binding of a ligand to the extracellular domain of the receptor. Ligand
binding is associated with sub-domains I, at the amino-terminal, and III. Sub-domains I
and III are flanked by the Cysteine-rich sub-domains II and IV (Lax et al., 1989; Lax et
al., 1988). Sub-domains II and IV, in the presence of a ligand, are able to exhibit an autoinhibitory interaction modulating the angle and affinity of the ligand binding cleft (Cho
and Leahy, 2002; Garrett et al., 2002; Ogiso et al., 2002; Schlessinger, 2000). The
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various binding affinities of EGFR ligands may be explained by the conformational
change and change in orientation of the ligand binding domain (Cho and Leahy, 2002).
Additionally, sub-domain II, with possible hinge-like action, creates an open
conformation necessary for receptor dimerization, and sub-domain IV is necessary for
EGFR localization to the caveolae/rafts in the plasma membrane (Garrett et al., 2002;
Heldin, 1995; Ogiso et al., 2002; Yamabhai and Anderson, 2002). Each receptor has a
transmembrane domain, which plays a passive role in signal transduction, but may have a
more important role in receptor dimerization (Heldin, 1995; Ullrich and Schlessinger,
1990). Just inside the plasma membrane the transmembrane domain is linked to the
juxtamembrane region.

It is the juxtamembane portion of EGFR that anchors the

transmembrane domain to the plasma membrane (Earp et al., 1995). The cytoplasmic
domain is comprised of the tyrosine kinase domain and the c-terminal tail containing
numerous tyrosine phosphorylation sites (Ullrich and Schlessinger, 1990). In addition to
tyrosine phosphorylation, EGFR is phosphorylated at serine (Ser) and threonine (Thr)
residues.

B. ErbB family members
All ErbB family members in their inactive state exist as monomers on the plasma
membrane.

Each family member is capable of undergoing homo- and hetero-

dimerization, a necessary step for activation and down-stream signaling.
ErbB2 was discovered due to its homology to EGFR; in fact, EGFR and ErB2
exhibit the highest homology among all family members (Coussens et al., 1985; King et
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al., 1985). ErbB2, which has no identified ligand, contains a constitutively exposed
dimerization loop (Garrett et al., 2002; Ogiso et al., 2002). In this regard, ErB2 is the
predominant dimerization partner for each of the ErbB family members and is able to
form dimers spontaneously resulting in cell transformation due to over expression alone
(Graus-Porta et al., 1997; Klapper et al., 1999; Lemmon, 2009). On the contrary, Erb3,
discovered in 1989, has low intrinsic kinase activity (Dubois and Guyot, 1994). This
suggests that ErbB2 and ErbB3 require interactions with other family members, as
compared to being able to contribute to linear signaling pathways (Yarden and
Sliwkowski, 2001). ErbB4, which has kinase activity, was the last family member to be
discovered (Plowman et al., 1993) and has identifiable ligands, the nergulins (Stove and
Bracke, 2004).

C. EGFR Activation
The majority of research on mechanisms involved with EGFR activation and
signaling has utilized the A-431 cell model, from which the human receptor was
originally identified. EGFR activation is initiated by ligand binding to the extracellular
domain of the receptor. There are seven ligands (to be discussed) that bind to and
activate EGFR: epidermal growth factor (EGF), transforming growth factor-alpha (TGF), amphiregulin (AREG), heparin binding-epidermal growth factor (HB-EGF),
betacellulin (BTC), epiregulin (EREG), and epithelial mitogen (EPGN). Upon ligand
binding, EGFR homo-dimerizes (with another EGFR monomer) or hetero-dimerizes
(with another ErbB family member) resulting in autophosphorylation of the intracellular
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cytoplasmic domain thus increasing the enzymatic activity of the tyrosine kinase domain
(Hubbard et al., 1998; Schlessinger, 2000).

EGFR bound with ligand undergoes a

conformational change allowing for dimerization and exposing tyrosine residues, lying
on an “activation loop” in the catalytic domain of the protein kinase domain, to ATP and
protein substrates. The activated EGFR tyrosine kinase domain catalyzes the transfer of
the -phosphate of ATP to tyrosine residues in substrate proteins, including the Cterminal and kinase domains of EGFRs dimerization partner (Fig. 1.1) (Hubbard et al.,
1998; Schlessinger, 2000; Ushiro and Cohen, 1980; Yarden and Schlessinger, 1987).
Phosphorylation of EGFR occurs at six tyrosine sites (Y701, Y845, Y891, Y920,
Y976) in the kinase domain and six tyrosine sites (Y992, Y1045, Y1068, Y1086, Y1101,
Y1148, Y1173) in C-terminal domain, of which some are auto-phosphorylation sites
(Jorissen et al., 2003). These events may directly initiate signaling events or provide
docking sites for adaptor molecules with Src-homology (SH2) or phosphotyrosine
binding (PTB) domains (Pawson and Gish, 1992). The docking sites allow for binding of
a variety of adaptor molecules: growth-factor receptor bound 2 (Grb2) and phospholipase
C (PLC)- gamma, phosphatases: SHP-1 and PTB-1B, and kinases: Src and Abl (Fig. 1.1)
(Sebastian et al., 2006). In one case, it was demonstrated that the C-terminal domain is
not necessary for full activation of EGFR signaling pathways when EGF is the activating
ligand.

However when AREG induces EGFR activation the c-terminal domain is

required for mitogenic signaling. The differences observed in ligand activation have
been attributed to EGF/EGFR promotion of ErbB2 hetero-dimeriztion as compared to
AREG/EGFR (Wong et al., 1999). This would suggest that the tyrosine residues in the
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kinase domain have more importance in EGFR signaling. Although many of the tyrosine
sites are autophosphorylated, non-tyrosine kinases (NTRK) such as c-src are able to
phosphorylate EGFR by associating with phosphorylated EGFR, and subsequently
phosphorylating EGFR at other sites. However, NTRK phosphorylation does still require
ligand binding and receptor dimerization (Lombardo et al., 1995; Stover et al., 1995).
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Figure 1.1: EGFR Structure, Activation, Signaling Pathways
A. In the basal state, EGFR exists as an inactive monomer (and possible as an inactive
pre-dimer). Ligand binding results in a conformational change exposing tyrosine residues
on the C-terminus to be phosphorylated. B. Tyrosine phosphorylation of the kinase and
C-terminal domains allows for adaptor molecules to bind and initiate various signaling
cascades.
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Although it is generally accepted that EGFR kinase activity requires both ligand
binding and dimerization, there are conflicting studies supporting the idea that ligand
binding is required for receptor dimerization. It has been reported that unligated EGFR
exists as predimers on the cell membranes (Clayton et al., 2007; Gadella and Jovin, 1995;
Sako et al., 2000; Teramura et al., 2006). This provides evidence for the aggressive
nature of cellular transformation and suggests EGFR activation and dimerization are
independent events (Van de Vijver et al., 1991; Yu et al., 2002).

D. EGFR signaling
EGFR associates with numerous proteins, hence activates multiple signaling
pathways. After ligand binding, tyrosine phosphorylation events occurring on the tyrosine
kinase domain and the C-terminal tail provide binding sites for adaptor molecules
containing SH2 and PTB domains (Pawson and Gish, 1992). Binding of a specific
adaptor molecule promotes a distinct signaling pathway or pathways.
The Ras/Raf/MEK/MAPK pathway is the most extensively studied EGFR
signaling pathway. Signaling from this pathway results in a cascade of events
predominantly correlated with mitogenisis. Following ligand binding, EGFR recruits
adaptor molecule Grb2. Grb2 interacts directly with EGFR at Y1068 and Y1086 or
indirectly by binding to Y1173-bound adaptor molecule; Shc. Grb2 then recruits a Gprotein activating protein (GAP), son of sevenless (SOS), to EGFR and activates H-, N-,
or K- Ras proteins (Buday and Downward, 1993; Lowenstein et al., 1992; Sieh et al.,
1994). Activated membrane-associated Ras, in turn, activates, the protein kinase, Raf,

9

which then activates the MAPK pathway. Mitogen activated extracellular signal
regulated kinase (MEK1/2) is activated via phosphorylation that then activates kinases
ERK1/2 (MAPK). Activated MAPK ultimately results in the phosphorylation of nuclear
transcription factors, such as c-Myc, c-fos, c-jun, Elk1, and ribosomal subunit kinase
(RSK), involved in the regulation of cellular proliferation (Fig 1.1) (Marshall, 1994;
Marshall, 1996; Pawson, 1995).
In addition to the MAPK pathway, EGFR activates the pro-survival
phosphatidylinositol 3-kinase Ia (PI3K Ia)/AKT signaling pathway. PI3K is composed of
a regulatory and catalytic subunit that form heterodimers: p85 and p110, respectively
(Carpenter et al., 1990). Upon cellular stimulation, p85 is recruited to Y920 on the Cterminal domain of EGFR.

P85 interacts with EGFR via an SH2 domain thus

positioning p110 so that it can interact with its substrates and relieving the p85
mediated inhibition of the p110 subunit. p110 is then able to catalyze the production
of phosphatidylinositol-3,4,5-triphosphate (PIP3). PIP3 recruits Protein Kinase B (PKB),
also known as AKT, to the cell membrane via its pleckstrin homology (PH) domain
(Jones et al., 1991; Stover et al., 1995). AKT becomes phosphorylated on Thr 308, in the
kinase domain, by phosphatinositide-dependent kinase 1 (PDK1). In addition, for full
AKT activation Ser 473, on the regulatory tail, needs to be phosphorylated. The
mechanism, by which Ser 473 is modified is not clearly defined. Indeed it had been
hypothesized that S473 may be autophosphorylated, or modified by PDK-2 or integrinlinked kinase (ILK). Recently, it has been accepted that S473 modification is a result of
mTORC2 (Delcommenne et al., 1998; Nicholson and Anderson, 2002; Sarbassov et al.,
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2006; Toker and Newton, 2000).

Activated AKT promotes cell survival through

phosphorylation and inhibition of the pro-apoptotic proteins Bad and Caspase-9 (Fig. 1.1)
(Cardone et al., 1998; Datta et al., 1997; Franke et al., 1997).
Phospholipase C gamma (PLC-) is a member of a family of enzymes catalyzing
the hydrolysis of PIP2 into secondary messengers: phosphatidic acid,1,2-diacylglycerol
(DAG) and inositol 1,3,5-triphosphate (IP3), thereby contributing to cell migration and
pro-proliferative signaling pathways (reviewed in (Rhee et al., 1989)). PLC- interacts
directly with EGFR at Y992, Y1173, and indirectly through binding with Grb2associated protein 1 (Gab1). Gab1, in addition to interacting with PLC- is capable of
interacting with PI3K subunit p85 (Holgado-Madruga et al., 1996).
Moreover, EGFR is capable of activating signal transducers and activators of
transcription (STAT) pathways (Darnell et al., 1994).

STAT activation, by cytokine

signaling is mediated by Janus kinase (JAK) dependent pathways. However, STAT
activation by EGFR signaling is mediated by JAK independent pathways (Andl et al.,
2004; Kloth et al., 2003). JAK, like Src, is a NRTK. In the JAK independent pathway,
ligand-dependent EGFR activation induces phosphorylation of STAT1 at Y701 and
STAT3 at Y705. These events lead to STAT dimerization. The complex translocates to
the nucleus activating transcription of genes associated with cell survival (Andl et al.,
2004; Leaman et al., 1996). In some instances STATs can be constitutively associated
with EGFR, however their activation is dependent on EGFR tyrosine kinase activity
(David et al., 1996; Olayioye et al., 1999; Xia et al., 2002). More recently, Yang et. al.,
in the JAK-independent pathway, found STAT5b to associate with Y845 on EGFR,
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possibly down-stream or independent of Src kinase (Kloth et al., 2003; Yang et al.,
2008).
Src is non-receptor tyrosine kinase that also plays a role in EGFR signaling. Src
phosphorylates EGFR at Y1101 and Y845 (Maa et al., 1995; Tice et al., 1999).
Phosphorylation at EGFR-Y845 promotes EGFR-induced mitogenesis, and the response
to phosphorylation of EGFR-Y1101, a residue not conserved in the ErbB family in vivo,
remains unclear (Biscardi et al., 1999; Stover et al., 1995; Tice et al., 1999). Still, the
exact location where src binds is unknown; however, it is thought to bind in the kinase
domain.

E. EGFR trafficking, localization, and degradation
EGFR in its basal state is predominantly localized to the plasma membrane in
lipid rafts/caveolae (Yamabhai and Anderson, 2002).

Inactive receptors are

constitutively internalized, transported to early endosomes (EE), and in most cases
recycled back to the membrane. The half-life of inactive EGFR is 10-14 hours in normal
epithelial cells, while in transformed cells the half life is much longer (20-48 hours)
(Wiley, 2003). EGF activated EGFR, via ligand binding and receptor dimerization,
enhances EGFR internalization (Sorkin and Goh, 2008; Wiley et al., 1991).

This

acceleration is due to endocytosis of EGF/EGFR complexes through clathrin-coated pits.
Clathrin-mediated endocytosis (CME) is a process whereby EGFR is internalized.
Notably, EGFR was shown to undergo internalization via a slower, non-clathrin
endocytosis (NCE) pathway as well. The pathway by which EGFR endocytoses is
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dependent on the concentration of EGF. In general, EGFR is internalized by the CME
pathway when EGF concentrations are low and the NCE pathway when EGF
concentrations are high (Sigismund et al., 2005).
Upon EGFR activation, a Grb2/Cbl complex is recruited to phosphorylated
Y1045. Cbl proteins are E3 ubiquitin ligases containing a phosphotyrosine binding
domain and a C3HC4 RING finger.

The Grb2/Cbl/EGFR interaction promotes the

recruitment of ubiquitin conjugating enzymes in order to mono-ubiquitinate EGFR. The
ubiquitination is recognized by Esp15, Esp15R, and Epsin proteins associated with AP-2.
The receptor and associated ligand are then internalized via clathrin coated pits and
localized to EE. In the case where EGFR is recycled, the ligand dissociates from the
receptor promoting EGFR’s return to the plasma membrane via recycling endosomes.
When the fate of EGFR is degradation, EGFR remains in the EE. The EEs mature into
mutivesicular vesicular bodies (MVB) and late endosomes (LE) where EGFR interacts
with a ternary complex composed of EPS15, signal transduction molecule (STAM), and
hepatocyte-growth-factor regulated tyrosine-kinase substrate (HRS) (Katzmann et al.,
2003).

The associated EGFR complex is directed to tumor susceptibility gene-101

(TSG1) and the endosomal sorting complex required for transport-I (ESCRT) complex
and EGFR is incorporated into internal vesicles in the MVBs. The MVB fuses with a
lysosome, consisting of a highly acidic pH, where EGFR and its associated ligand are
degraded (Fig. 1.2) (Sorkin et al., 1991). In one study it has been shown that EGFR can
be polyubiquitnated and degraded in the proteosome (Levkowitz et al., 1999).
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Figure 1.2: EGFR Internalization, Trafficking, Localization
Inactive EGFR is internalized and recycled back to the membrane. When EGFR is
stimulated by EGF EGFR is ubiquitinated by cbl and transported to EE. The receptor
associated with a complex and moves to the MVB and lastly to the lysosome for
degradation. AREG stimulation of EGFR induces EGFR internalization and trafficking to
the RE where EGFR is recycled back to the cell surface.
Most of the studies regarding EGFR trafficking have been done with EGF. Not as
much is known about trafficking and EGFR localization when EGFR associates with its
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other growth factors. TGF- stimulation of EGFR is the second-most well understood
mechanism of EGFR trafficking. TGF- unlike EGFR, rapidly dissociates from EGFR
in the EE due to the low pH (Ebner and Derynck, 1991). At this time, EGFR is deubiquitinated and recycled back to the cell surface (Decker, 1990; Longva et al., 2002).
A recent paper by Roepstorff et. al. studied the differential effects of EGFR ligands on
endocytic sorting. In this study it was shown that EREG stimulates internalization
followed by rapid EGFR recycling to the cell surface. Coinciding with the recycling
phenotype, Y1045 phosphorylation and ubiquitination levels were low. In contrast, BTC
stimulation resulted in persistent Y1045 phosphorylation, c-Cbl recruitment and EGFR
ubiquitnation thus supporting EGFR degradation (Roepstorff et al., 2009).
Studies done in the SUM-149 breast cancer cell line demonstrated AREG
stimulation of EGFR resulted in low levels of Y1045 phosphorylation, internalization,
and ubiqutination (Willmarth and Ethier, 2008). Moreover, AREG promotes EGFR to be
rapidly recycled to the plasma membrane (Baldys et al., 2009). Interestingly, AREG is
highly resistant to the acidic pH present in the EE, suggesting that relatively low binding
affinity of AREG may cause the dissociation and recycling of EGFR (Roepstorff et al.,
2009).
In addition to proteins having the capability of inducing EGFR endocytosis, some
proteins such as Sprouty2 have been shown to negatively regulate EGFR internalization
by interacting with c-Cbl. Sprouty2 associates with Grb2 and c-Cbl at the RING domain
inhibiting E3 ligase function, thereby reducing EGFR ubiquitination and internalization
(Hanafusa et al., 2002; Rubin et al., 2003). Cool-1, Tbc1d3, GAPex5, intersectin, and
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CIN85 are among other c-Cbl interacting proteins that interrupt EGFR endocytosis (Feng
et al., 2006; Martin et al., 2006; Soubeyran et al., 2002; Su et al., 2007; Szymkiewicz et
al., 2002; Wainszelbaum et al., 2008). Other proteins that can either inhibit or promote
EGFR internalization, aside from c-Cbl, include: Na+/H+ exchanger regulatory factor 1
(NHERF1), Ymer, Spartin, and Cdc42-associated tyrosine kinase 1 (ACK1) (Bakowska
et al., 2007; Lazar et al., 2004; Shen et al., 2007; Tashiro et al., 2006).

F. EGFR and Cancer
EGFR is a proto-oncogene. Mice deficient in EGFR exhibit defects ranging from
death at mid-gestation, to survival for up to three weeks, depending on the genetic
background of the mutant mice. Surviving mice had abnormalities in the liver, skin,
lung, brain, and GI tract prior to early death (Miettinen et al., 1995; Sibilia et al., 1998).
Characteristic of an oncogene, EGFR is essential to normal development and physiology
in the cell, but when altered by mutations or over expression, EGFR induces cellular
transformation. The v-erbB viral oncogene, lacking most of the extracellular domain, has
direct homology to human EGFR as seen after EGFR was cloned and sequenced (Ullrich
et al., 1984). It was this line of evidence that implicated EGFR in tumor progression
(Downward et al., 1984).
Classically, cancer transformation has been described by the ability of a
transformed cell to acquire six “hallmarks” of cancer. These hallmarks include: cell
invasion and metastasis, sustained angiogeneisis, limitless replicative potential, evading
apoptosis, self-sufficiency in growth signals, and insensitivity to anti-growth signals
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(Hanahan and Weinberg, 2000).

Now, ten years later, cellular transformation is

continually described by these hallmarks, but with the addition of six more defining
characteristics: evading immune surveillance, metabolic stress, proteotoxic stress, mitotic
stress, oxidative stress, and DNA damage stress (Luo et al., 2009). EGFR regulates many
of these characteristics in a variety of cancers.
Aberrant EGFR activity can contribute to in vitro transformation and in vivo
tumorgenisis. This may be the consequence of one or more of the following: EGFR over
expression and/or mutation, alterations in dimerization, increased ligand expression or
release, disrupted trafficking and turnover of inactive receptors, or deficiency in
inactivating phosphatases (Blume-Jensen and Hunter, 2001; Salomon et al., 1995a;
Sebastian et al., 2006).

Over expression of EGFR occurs by amplification and/or

increased transcription. EGFR over expression without EGFR amplification is one of the
most frequently observed mechanisms in EGFR mediated cancer progression (Athale and
Deisboeck, 2006). SUM-149 breast cancer cells are one example where this mechanism
is observed along with the presence of an AREG/EGFR autocrine loop, thereby leading
to EGFR stimulation by AREG and EGFR over expression (Willmarth and Ethier, 2006).
Indeed another frequently observed mechanism of EGFR over expression is the presence
of a TGF- autocrine loop (TGF- induces EGFR recycling) (El-Obeid et al., 2002).
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i. EGFR in breast cancer
EGFR expression is observed in head and neck, breast, renal, lung, colon, ovarian,
prostate, pancreatic, bladder, and brain cancers. For the purpose of this dissertation the
focus will be on breast cancer. In the 1980’s experiments carried out by Sainsbury and
co-workers first identified an inverse relationship between EGFR and Estrogen Receptor
(ER) status (Sainsbury et al., 1987). More over, this group found a significant association
between ER and EGFR expression and tumor size and differentiation; EGFR-positive
breast cancers showed significantly worse overall and relapse-free survival (Sainsbury et
al., 1987). It became clear that the histological sub-type of breast cancer could indicate
the prognosis of the disease (Sainsbury et al., 1988). By
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I-labelling EGF, three sub-

types of breast cancer were identified; one, EGFR-positive and ER-negative, another
EGFR-negative and ER-positive, and lastly a group that was EGFR-positive and ERpositive. As seen in their previous studies, overall and relapse-free survival was nearly 2
years shorter for the EGFR-positive tumors (Harris et al., 1989). In 1992, Harris et. al.
found the EGFR and ErbB2 had adverse additive effects and that ErbB2 was a marker of
poor prognosis and lack of response to endocrine therapies (Harris et al., 1992).
The work of Harris et al. led to the elucidation of breast cancer sub-types by the
use of high-throughput molecular biology techniques. Based on hierarchical clustering of
65 breast cancers compared to normal breast tissue, breast cancer is categorized into four
subtypes: normal-like, luminal (A and B), ErbB2 positive, and basal-like (Perou et al.,
2000). These subtypes have been validated by Sorlie et al. in 2001 and 2003, further
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characterizing the luminal type into two subtypes, types A and B (Sorlie et al., 2001;
Sorlie et al., 2003).
Normal-like breast tumors, as expected, have genetic expression similar to those
of normal basal epithelial cells and adipose cells (Perou et al., 2000). Luminal breast
cancers are defined as two groups, A and B (Sorlie et al., 2003). Luminal A cancers are
96% positive for estrogen receptor (ER) alpha expression and contain high levels of
luminal cell keratins 8/18 (Perou et al., 2000).

Luminal B cancers along with ER

expression include the expression of ErbB2 (Sorlie et al., 2001). While luminal A
cancers have a better prognosis than luminal B cancers, both contribute to the significant
decline in breast cancer mortalities observed since the 1990s. The expression of ER in
the luminal subtype and the introduction of targeted therapies with selective ER
modulators (SERMs), such as tamoxifen, are likely the factors responsible for the better
prognosis. ErbB2 positive breast cancers are defined by the expression of ErbB2, Grb7
and little, if any, ER (Perou et al., 2000). These cancers tend to have a worse prognosis
than luminal breast cancers (Sorlie et al., 2001). However, due to ErbB2 targeted therapy
with Trastuzumab, a monoclonal antibody, ErbB2-positive tumors have a better
prognosis than the last subtype, the basal-type (Romond et al., 2005; Sorlie et al., 2003).
Basal-type breast cancers represent approximately 15% of all breast cancers and
continue to have the worst prognosis (Perou et al., 2000). They are characterized by the
expression of cytokeratin 5/6 and 17, fatty acid-binding protein 7, integrin 4 and
laminin. Typically, basal-type breast cancers lack the expression of ER, ErbB2, and
progesterone (PR). Therefore, as of today, patients are not able to undergo targeted
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chemotherapies.

Many of the characteristics observed in triple negative, basal-type

breast cancers are due to BRCA1 mutations, making a portion of the basal-type a
hereditary disease (Sorlie et al., 2003).

ii. Targeting EGFR in breast cancer
EGFR is expressed in 14-91% of breast cancers (Reviewed by (Grandis and Sok,
2004)).

The large variance is likely due to the variety of techniques: autoradiography,

immunoctyochemistry, immunoenzymatic assay, and gene transcript analysis, utilized in
analyzing EGFR expression in breast cancer. By immunocytochemistry, EGFR has been
observed to be over-expressed in 60% of basal-type breast cancers (Livasy et al., 2006).
Beginning in the 1980s, EGFR was targeted in cancer therapeutics. In 1990, the first
clinical trial of an anti-EGFR agent was initiated. In lung cancer patients, monoclonal
antibody 225 (Mab225/cetuximab) was found to inhibit EGFR activity. Anti-EGFR
antibodies are designed to bind to the extracellular domain of EGFR, therefore preventing
ligand binding and cell proliferation (Grunwald and Hidalgo, 2003). Following the
development of cetuximab, a number of other monoclonal antibodies entered the clinic:
ABX-EGF, EMD7200, and h-R3 (Crombet-Ramos et al., 2002; Rowinsky et al., 2004;
Vanhoefer et al., 2004). After the development of monoclonal antibodies, a new class of
chemicals, anilinoquinazolines, with similar effects were produced (Ward et al., 1994).
These small molecule inhibitors, known as tyrosine kinase inhibitors (TKIs), block the
activation of EGFR by interacting with the tyrosine kinase domain resulting in inhibition
of EGFR autophosphorylation (Ciardiello et al., 2000). It was not until the 21st century

20

when the EGFR TKI gefitinib (Iressa) was used in clinical trials and showed promising
anti-tumor activity (Fukuoka et al., 2003; Kris et al., 2003). Gefitinib was approved for
treatment in non-small cell lung carcinoma (NSCLC) in Japan and one year later the FDA
approved gefitinib in the United States. However after clinical trial data demonstrated no
significant survival benefit with the use of gefitinib, the drug lost FDA approval and was
removed from the market. Similar TKI’s such as erlotinib, which can inhibit wild-type
EGFR at lower concentrations than gefitnib, are now currently used as they do
significantly increase overall survival.
When cancers have EGFR mutations (ie: in lung cancers) there is success in
EGFR targeted therapies. In the instance of breast cancer, where EGFR is present in wildtype form, cancers become resistant to the present targeted therapies. (Arteaga, 2003;
Osborne et al., 2003).

EGFR activation, signaling, trafficking, and degradation

mechanisms are complex. A deeper understanding of these mechanisms will advance the
field for treatment options in not only breast cancer, but a diverse amount of epithelial
cancers.

G. EGFR Ligands
Currently there are six known ligands, aside from AREG, that bind to and activate
EGFR.

All ligands are type I transmembrane proteins composed of common

extracellular, transmembrane, and cytoplasmic domains.

The sequence homology

between all ligands is approximately 25% (Harris et al., 2003). These differences are
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accounted for by the presence of N-terminal extensions, heparin binding domains,
differential glycosylation sites, and other biochemical characteristics.

i. Epidermal Growth Factor: EGF (1960)
EGF was the first EGFR ligand discovered in the 1960s. Cohen et. al. isolated
EGF, which induced premature eyelid opening and tooth eruption, from the submaxillary
gland of mice (Cohen, 1962). EGF is unique compared to the other ligands in that it has
nine EGF-like domains (David et al., 1996; Olayioye et al., 1999; Xia et al., 2002). It is
located on chromosome 4q25, spanning 99.4 kb of DNA.

After post-translational

modifications, the mature EGF protein is composed of 53 residues with a molecular
weight of about 6 kDa (Kajikawa et al., 1991; Taylor et al., 1970). EGF is produced in a
variety of human tissues and in human milk (Connolly and Rose, 1988). Northern Blot
and immunohistochemistry studies have demonstrated EGF mRNA and protein
expression in adult epithelial cells and the gastrointestinal tract (Connolly and Rose,
1988; Kajikawa et al., 1991). Mice lacking EGF have developmental effects in prostatic
epithelial bud formation (Abbott et al., 2003).

ii. Transforming Growth Factor-alpha: TGF- (1978)
TGF- was the second EGFR ligand to be found. Its discovery was the result of
protein isolation from the conditioned medium of murine sarcoma virus transformed cells
(de Larco and Todaro, 1978). TGF- is located on chromosome 2p11-13, spanning 70100 kb of DNA. Mature TGF- yields a 50 residue protein, ranging from 6-20 kDa in
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size due to post-translational modifications (Teixido and Massague, 1988). Expression of
TGF- has been demonstrated during embryogenesis and in numerous adult tissues,
especially those involved in regeneration and epithelial stem cell populations (Kudlow
and Bjorge, 1990). TGF- -/- mice are viable, but have lens and retinal abnormalities
along with a noticeable phenotype change that is demonstrated by waviness of their coat
and whiskers (Berkowitz et al., 1996; Mann et al., 1993).

iii. Heparin Binding-Epidermal Growth Factor: HB-EGF (1991)
Initially, HB-EGF was isolated from the conditioned medium of macrophage-like
U-937 cells (Higashiyama et al., 1991). It is a unique family member in that membrane
anchored HB-EGF acts as a specific receptor for the diphtheria toxin (Iwamoto et al.,
1994; Naglich et al., 1992). HB-EGF is located on chromosome 5q23 and spans 15.28 kb
of DNA (Freeman et al., 1997; Nishi and Klagsbrun, 2004). The mature form of the
protein comprises 68 to 87 residues and has a molecular weight of 4-22 kDa following
post-translational modifications. Expression of HB-EGF has been observed in a variety of
mammalian tissues, such as bladder, smooth muscle, skin, heart, and lung; however it is
not expressed in endothelial cells (Abraham et al., 1993; Freeman et al., 1997). HB-EGF
-/- mice form enlarged and malformed semilunar and atrioventricular heart valves and
poorly differentiated lungs (Iwamoto et al., 2003; Mine et al., 2005).

iv. Betacellulin: BTC (1993)
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BTC was isolated from the conditioned medium of a mouse pancreatic 
insulinoma (Shing et al., 1993). A novel characteristic of BTC, along with HB-EGF, is its
ability to bind both EGFR and ErbB4 (Dunbar and Goddard, 2000; Elenius et al., 1997;
Riese et al., 1996). BTC not only activates two of the ErbB family members, but is
capable of initiating all possible combinations of heterodimeric ErbB receptors (reviewed
by (Dunbar and Goddard, 2000)). BTC is located on chromosome 4q13-q21 and spans
48.4 kb of DNA (Harris et al., 2003).

BTC protein is 32 kDa in size after post-

translational modifications and is composed of 80 residues (Shing et al., 1993). BTC is
expressed in most adult tissues, but is especially high in the pancreas, liver, kidney, and
small intestine (Sasada et al., 1993; Seno et al., 1996). In addition, expression is found in
bodily fluids including milk (Dunbar et al., 1999). Mice lacking BTC expression were
viable and did not appear to have any growth abnormalities, even in the pancreas
(Jackson et al., 2003).

v. Epiregulin: EREG (1995)
EREG was first isolated from the conditioned medium of the mouse tumor cell
line NIH3T3/clone T7. EREG does not bind heparin (Toyoda et al., 1995b). EREG is
located on chromosome 4q13.3 and spans 4.8 kb of DNA (Toyoda et al., 1997). The
molecular weight of the mature protein, as seen by radiolabelling conditioned media, is 5
kDa representing 46 AA residues (Toyoda et al., 1995a; Toyoda et al., 1997). Compared
to the other EGFR ligands, EREG is unique in that it has relatively low levels of
expression in normal adult tissue. However, EREG expression was found in peripheral
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blood, macrophages, and the placenta (Toyoda et al., 1997). EREG -/- mice were viable
and proved to have no abnormalities in growth or reproduction, but were more
susceptible to transformation when intestinal damage was induced with dextran sulfate
sodium (Lee et al., 2004).

vi. Epithelial Mitogen: EPGN (2001)
The epithelial mitogen, EPGN, was identified from a mouse keratinocyte cDNA
library due to its homology to EREG (Strachan et al., 2001). It is the most recent EGFR
ligand to be discovered. It is a unique growth factor in that it elicits high mitogenicity
while having low affinity to EGFR (Kochupurakkal et al., 2005). EPGN’s transcript
spans 5kb of DNA and is located on chromosome 4q13.3, only 25kbp away from
EREG’s open reading frame (Kochupurakkal et al., 2005). The mature protein is
processed to 86 residues and has a molecular weight of 8 kDa. EPGN is expressed in
numerous mammalian tissues, most highly in tissues of the developing embryo such as
tongue papillae, dorsal root ganglion, and in hair follicles (Kochupurakkal et al., 2005).
The in vivo effects of EPGN have been observed through generation of transgenic mice
over expressing EPGN (Dahlhoff et al., 2010). These mice expressed enlarged sebaceous
glands. Knock-out mice remain to be studied.
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1.2 Amphiregulin (AREG)
A. Discovery and Structure
AREG is a heparin-binding molecule that binds EGFR (Cook et al., 1991).

It

was first isolated from the conditioned medium of MCF-7 breast cancer cells following
treatment with a tumor promoter, phorbol 12-myristate 13-acetate (PMA), by Shoyab et.
al. (Shoyab et al., 1988). AREG was named for its ability to stimulate the proliferation
of human fibroblasts and keratinocytes, as well as tumor cells, and its ability to inhibit the
proliferation of some carcinoma cell lines in culture (Shoyab et al., 1988).
Structurally AREG’s amino-terminus was characterized by cleavage of an Edman
degradated, N-glycancase treated, reduced, and S-pyridylethylated AREG (NG-SPEAREG). Two amino-terminal sequences emerged; one being six amino acids shorter
(78AA) than the larger (84AA) sequence (Shoyab et al., 1989). The 84AA sequence has
a lower binding affinity to EGFR and is the higher yielding (20%) sequence, as compared
to the 74AA sequence. The carboxyl-terminal sequence was described by cleavage of
NG-SPE-AREG with carboxypeptidase P. Both the 78 and 84 AA sequences have similar
carboxyl-terminals, and both are biologically active (Shoyab et al., 1989). Directly
following Shoyab’s initial characterization of AREG, molecular cloning techniques were
utilized to further define AREG. Total cellular RNA was isolated from MCF-7 cells and
cDNA of AREG was transcribed and analyzed. The 84 AA corresponded to the mature
secreted form of AREG (Plowman et al., 1990).
AREG was compared to other EGF-like growth factors and proteins, and like all
family members, AREG’s bioactive domain is characterized by six essential cysteine
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residues, spaced: CX7CX4CX10CX1CX8C, where C represents cystenines and X can be
any AA (Fig. 1.3) (Shoyab et al., 1989). Additionally, AREG has 38% homology with
EGF and 32% homology with TGF- (Shoyab et al., 1989). AREG was found to have
six exons and five introns spanning 10.2 kb of genomic DNA (Plowman et al., 1990).
Exon one contains a 210bp 5’UTR and signal peptide: exon two contains the aminoterminal precursor: exon three contains a very basic and hydrophilic amino-terminal
portion and the first two loops of the EGF-like region: exon four contains the third loop
of the EGF-like motif and the transmembrane domain: exon five contains the cytoplasmic
region: and lastly, exon six contains the 262bp 3’UTR (Plowman et al., 1990). AREG is
located on chromosome 4q13-4q21 in close proximity to genes BTC and EREG
(Plowman et al., 1990; Sasada et al., 1993; Toyoda et al., 1997). This supports the
hypothesis that EGFR ligands evolved through gene duplication events.
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Figure 1.3: AREG Structure and Cell Processing
The structure of the 50 kDa pro-AREG, the location of the nuclear localization signals
(NLS), Heparin binding domain, EGF-like domain, and the transmembrane (TM)
domain. AREG is processed by ADAM17/TACE at various sites indicated by the orange
arrows.
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B. AREG isoforms
AREG is synthesized as a 252 amino acid transmembrane precursor that requires
proteolytic cleavage for secretion (Fig. 1.3). Proteolytic processing is an important step in
EGFR activation by AREG. Tumor necrosis factor alpha (TNF-) converting enzyme
(TACE) has been implicated in the shedding of AREG, TGF- HB-EGF, and EPGN
from the plasma membrane (Hinkle et al., 2004; Merlos-Suarez et al., 2001; Peschon et
al., 1998; Sahin and Blobel, 2007). TACE is a member of the integral membrane
proteins and is a Disintegrin and Metalloproteinase (ADAM). It was discovered in the
search for the protease responsible for ectodomain shedding of TNF- (Black et al.,
1997).

The development of TACE -/- mice demonstrated, in vivo, the proteinase’s

essential role in ectodomain shedding of structurally and functionally diverse membranebound proteins (Peschon et al., 1998). The TACE-/- mutation proved to be lethal prior to
birth in most cases. Fetuses were examined, and found to have severe epithelial structure
developmental defects similar to EGFR-/- and TGF--/- mice (Peschon et al., 1998).
Similar to defects observed in AREG-/- and HB-EGF-/- mice, TACE-/- mice showed
defects in epithelial lung branching, ductal branching in the mammary gland, and heart
valve development (Jackson et al., 2003; Luetteke et al., 1999).
Due to proteolytic processing by TACE/ADAM17 and other post-translational
modifications, there are several forms of AREG. Cleavage results in two soluble forms
of either 78 or 84 amino acids in length, which range from 19-21-kDa in molecular
weight (Plowman et al., 1990; Shoyab et al., 1989). Post-translational modifications of
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pro-AREG produces a major soluble 43-kDa form, 28-, 26-, 16-kDa membrane anchored
forms, and soluble 21-, 19-, and 9-kDa forms (Brown et al., 1998).
AREG protein has four domains: a 43 AA N-terminal pro region, an EGF-like
domain, a transmembrane domain, and a cytoplasmic domain. AREG’s N-terminal pro
region includes the pro-domain, two putative nuclear localization signals (NLSs), and a
heparin binding domain. This pro region is rich in prolines, serines, and threonines,
making this region highly hydrophilic. Similar to other EGFR growth factors, the Nterminal region has N-linked and O-linked glycosylation sites (Shoyab et al., 1989). The
status of AREG protein glycosylation is not important for the bioactivity of the protein,
but may be important in the stability, solubility, resistance to proteolysis, or localization
of AREG (Rademacher, 1998).
The heparin binding domain (residues 26-44), located within the in pro-region, is
necessary for proper folding and secretion of a bioactive AREG. Deletion of the proregion prevents AREG secretion (Thorne and Plowman, 1994). The heparin binding
domain is unique to AREG and HB-EGF. Heparin sulfate proteoglycans (HSPGs) are
located on the plasma membrane. The binding of AREG to HSPGs is essential to AREGtriggered mitogenic signaling by EGFR (Johnson and Wong, 1994). HSulf-1, responsible
for desulfation of glycosaminoglycans, such as AREG and HB-EGF, is down-regulated
in breast and ovarian cancers (Lai et al., 2003); this results in an increased affinity for
heparin binding ligands adding to autocrine and paracrine proliferation signals (Narita et
al., 2007).
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Lastly, within the pro region there is a tetrapeptide sequence, ARG-LYS-LYSLYS, repeated two times at residues 26-29 and 40-43. This sequence constitutes the
NLSs (Shoyab et al., 1989); however the role of AREG in the nucleus continues to
remain unclear. NLSs appear to be important in full signaling and co-translocating bound
receptors to the nucleus to participate in gene regulation (Jans and Hassan, 1998). This
observation corroborates the hypothesis that EGFR functions as a transcription factor in
the nucleus (Lin et al., 2001). More recently, truncated pro-AREG has been shown to
interact with A-type lamin at the inner nuclear membrane where it participates in
chromatin organization and control of transcription (Isokane et al., 2008).
The EGF-like domain is located within 25 residues of the transmembrane domain
(Fig. 1.3). Cleavage occurs between the two domains, promoting autocrine and paracrine
signaling. The six-cysteine motif previously described is the central and functional
feature of AREG and all EGF-like growth factors. It is this motif that associated with
EGFR.
The cytoplamsic domain is required for basolateral sorting, guaranteeing proper
AREG signaling as seen in Madin-Darby Canine Kidney cells (MDCK). When the
cytoplasmic domain was mutated, 65% of the AREG proteins were sorted to the apical
surface. However, cleavage of the ligand was not altered by the mutation, suggesting that
the C-terminus is not required for processing of the ligand (Brown et al., 2001).
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C. AREG expression/regulation
AREG acts as an autocrine growth factor in human urothelial cells, normal human
keratinocytes, and human lung bronchial epithelial cells (Kansra et al., 2004; Tsao et al.,
1996; Varley et al., 2005). During development in the mouse mammary gland, AREG
has been shown to play an important role in terminal end bud (TEB) formation and ductal
elongation (Ciarloni et al., 2007; Luetteke et al., 1999).

In addition, expression of

AREG mRNA has been observed in a variety of cancers including: colon, breast, liver,
prostate, pancreatic, lung, bladder, ovarian, skin, myeloma, and squamous cell carcinoma
(D'Antonio et al., 2002; Ebert et al., 1994; Fontanini et al., 1998; Mahtouk et al., 2005;
Salomon et al., 1995; Sehgal et al., 1994; Tsai et al., 2006).
In the human AREG promoter, a cyclic adenosine monophosphate (cAMP)repsonsive element (CRE), a serum responsive element (SRE), a highly conserved
specificity protein 1 element (SP1), WT1 responsive element (WRE), and TATA box
have been identified (Du et al., 2005; Lee et al., 1999).
Regulation of AREG expression by the CRE site (-267 to -274 nt) has been
observed in a cell line, MSK-Leuk1, derived from a dysplastic leukoplakia lesion when
exposed to a saline extract containing tobacco smoke (Du et al., 2005). In addition,
AREG expression was induced in a CRE-dependent manner in mouse tissue exposed to
whole animal hypoxia (O'Reilly et al., 2006).

In this pathway, cAMP, a second

messenger, phosphorylates Protein Kinase A (PKA) and activates CRE-binding protein
(CREB). CREB is a 43 kDa transcription factor which binds to the CRE sequence and, in
the instances described here, induces AREG expression (Reviewed by (Mayr and
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Montminy, 2001)). Further evidence for cAMP’s induction of AREG expression has
been demonstrated in response to Prostaglandin E2 (PGE2) in colon cancer, T
lymphocytes, prostate cancer, breast cancer, and adrenal cells (Johansson et al., 2004;
Shao et al., 2003). Parathyroid hormone (PTH), promoter of bone metabolism, is yet
another factor that has been shown to induce AREG expression via the
cAMP/PKA/CREB pathway in UMR 106-01, osteoblastic cell line (Qin and Partridge,
2005). Lastly, Wilms Tumor Suppressor (WT1) induces the expression of AREG in
U2OS, ostesarcoma cells, through an AREG transcriptional activator (Lee et al., 1999).
Recent work in cells derived from cervical cancer, HeLa, demonstrated for the
first time AREG expression to be suppressed in response to a transcription factor binding
the AREG promoter. Breast cancer-associated 1 (BRCA1), a breast and ovarian tumor
suppressor, functions in: transcription, DNA damage repair, and cell cycle regulation
(Mullan et al., 2006). BRCA1 binds to the AREG promoter downstream of the TATA
Box (-283 to -233nt) at -202 to -182 and +19 to +122, while depletion of BRCA1 resulted
in an increase in AREG transcription (Lamber et al., 2010; Lheureux et al., 2010).
Many other molecules have been shown to regulate AREG expression. These
molecules include estrogen, androgen, vitamin D3, HOXB9, cytokines: IL-1 and TNF, other EGFR growth factors (EGF and TGF-), and EGFR itself (Akutsu et al., 2001;
Hayashida et al., 2010; Kansra et al., 2004; Kitadai et al., 1993; Martinez-Lacaci et al.,
1995; Normanno et al., 1994; Sehgal et al., 1994; Streicher et al., 2007; Woodworth et
al., 2005). The pathways by which each factor regulates AREG transcription requires
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further elucidation; however it is apparent that a variety of signaling molecules can
promote AREG expression in a numerous tissues.

D. AREG/EGFR signaling mechanisms and pathways
i. AREG signaling mechanisms
AREG signals with EGFR via three general mechanisms: autocrine, paracrine, and
juxtacrine. Autocrine regulation is observed when a soluble ligand is produced by a cell
and stimulates the receptor on the cell from which it was made. On the contrary,
paracrine signaling occurs when a soluble ligand is produced by a cell and stimulates its
receptor on a different cell, independent of the type of cell from which it was shed.
Lastly, juxtacrine signaling is defined by stimulation of a receptor on neighboring cells
by a ligand that is bound to the cell surface of a neighboring cell.
An AREG/EGFR autocrine loop was first observed in normal human keratinocytes.
Heparan sulfate inhibited AREGs ability to compete for binding with EGF to EGFR and
reduced EGFR activity and mitogenisis. This led to the initial hypothesis that AREG
regulates EGFR activity through an autocrine loop (Cook et al., 1991).

Autocrine

regulation of AREG has been seen in normal bronchial epithelial cells and normal
urothelial cells (Tsao et al., 1996; Varley et al., 2005). In addition to normal cells, an
AREG/EGFR autocrine loop has been observed in cancers, including: hepatocellular,
colon, gastric, pancreatic, and breast (Akagi et al., 1995; Castillo et al., 2006; Culouscou
et al., 1992; Funatomi et al., 1997; Johnson et al., 1992; Willmarth and Ethier, 2006).
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Anklesaria et al. defined juxtacrine signaling in mouse bone marrow stromal cells
when they found pro-TGF- expressed on the membranes of stromal cells was able to
bind to and activate EGFR on neighboring hematopoeitic progenitor cells (Anklesaria et
al., 1990). These data suggest that membrane-anchored growth factors can stimulate
adjacent cells, or signal in a juxtacrine manner. TGF-was confirmed to signal in a
juxtacrine fashion in NRK cells when an uncleavable TGF- was co-cultured with a layer
of EGFR expressing cells above them, inducing cell transformation (Brachmann et al.,
1989). HB-EGF and AREG have also been shown to signal by this mechanism. HBEGF, fixed and unable to be shed, enhanced EGFR signaling. In addition to enhanced
EGFR signaling in the presence of un-cleavable TGF- (Takemura et al., 1997; Yang et
al., 2000), SUM-149 breast cancer cells, expressing high levels of AREG, were overlain
on top of MCF10A cells deprived of EGF, which increased tyrosine phosphorylation of
EGFR suggesting that pro-AREG could stimulate EGFR activity (Willmarth and Ethier,
2006).
Only certain EGF-like growth factors are able to signal in a juxtacrine manner. In a
study by Dong, et. al. the EGF binding domain of membrane-bound ligands were
combined with other various domains of EGF and HB-EGF.

Ligands with the

membrane-anchoring domain of EGF required proteolytic cleavage for activity.
However, the membrane anchoring domain of HB-EGF was sufficient to induce
biological activity (Dong et al., 2005). Therefore, it is hypothesized that the juxtacrine
mechanism occurs in vivo and may induce different signaling cascades upon activation.
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ii. AREG signaling pathways
AREG activates the Ras/Raf/MEK/ERK pathway in a variety of cells including:
pancreatic duct cells, normal human keratinocytes, bronchial epithelial cells, and bone
(Blanchet et al., 2004; Kansra et al., 2004; Qin and Partridge, 2005; Wagner et al., 2002).
Upon AREG/EGFR activation and ERK signaling, Elk1, c-jun, and c-fos have been
shown to be activated. The C-terminal tail of EGFR is critical for the expression of these
down-stream molecules (Wong et al., 1999).
PI3K/Akt signaling can be activated by AREG/EGFR signaling. This cascade
promotes cell survival through the up regulation of active NF-B and IL-1 (Streicher et
al., 2007). Aside from AKT and ERK signaling, AREG has been shown to induce STAT
1, 3, and 5 (Berasain et al., 2005; David et al., 1996). AREG promotes STAT signaling
in a JAK independent manner in Hela cells (Berasain et al., 2005).

However, the

activation of STATs is dependent on EGFR kinase activity, as seen in fibroblasts
expressing EGFR tyrosine kinase mutants (David et al., 1996).
The by-products of PLC- hydrolysis of PIP2 is IP3 receptor and DAG. DAG can
activate protein kinase C (PKC). Activated PKC has been observed in NSCLC. AREG
and insulin-like growth factor were found to activate this pathway by increasing
phosphorylation of p90rsk and Bad while inhibiting Bax (Hurbin et al., 2005).

In

addition to EGFR interactions with PLC-, EGFR associates with c-src. C-src up
regulates genes associated with cytosekeltal rearrangement of the cell including: focal
adhesion kinase (FAK), RhoGAP, cortactin, and Eps-8 (Jorissen et al., 2003). Due to the
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observation that FAK activation increases in colon cancer cells AREG has been
suggested to promote interactions between c-src/EGFR (Picihard et al., 2006).
AREG has been proven to be involved in the expression of several genes involved
in cell cycle progression and the inflammatory response.

Cyclin D1 expression is

regulated by AREG in pancreatic duct cells and vascular smooth muscle cells (Shin et al.,
2003; Wagner et al., 2002). IL-8, IL-6, and IL-1 expression has been demonstrated in
human airway epithelial cells, multiple myeloma cells, and breast cancers cells,
respectively (Blanchet et al., 2004; Chokki et al., 2006; Mahtouk et al., 2005; Streicher et
al., 2007). In two instances, in colon cancer cells and oral squamous carcinoma cells,
AREG induced the expression of cycloxygenase-2 (COX-2) (Coffey et al., 1997; Tsai et
al., 2006). As discussed previously AREG also regulates the expression of MMPs,
including: MMP-2, MMP-9, and other factors involved in matrix degradation: uPA,
EMMPRIN, and PAI-1 (Giusti et al., 2003; Silvy et al., 2001).
In addition to FAK and MMPs, genes involved with migration and invasion,
AREG induces expression and alters localization of E-cadherin.

E-cadherin is an

epithelial adhesion molecule and has been implicated in cell motility and invasion. In
mouse keratinocytes over expressing AREG, E-cadherin was down-regulated via
processing into an 80 kDa form in psoriatic lesions. Localization alterations by AREG
have been demonstrated in MDCK cells treated with neutrophils and AREG. AREG
promoted the movement of MDCK cells and induced a spindle-like morphology as
compared to TGF- (Chung et al., 2005a; Chung et al., 2005b). SUM-149 breast cancer
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cells, which over express AREG, on the contrary, express high levels of E-cadherin at the
cell surface (Hoffmeyer et al., 2005).

E. AREG expression in normal tissue
AREG acts as an autocrine growth factor in human urothelial cells, normal human
keratinocytes, and human lung bronchial epithelial cells (Kansra et al., 2004; Tsao et al.,
1996; Varley et al., 2005; Willmarth and Ethier, 2006). In addition, AREG is widely
expressed in human tissues including the placenta, ovary, testis, heart, pancreas, spleen,
kidney, lung, ovary, colon, and breast (Plowman et al., 1990; Stern, 2003).
Differentiation of the mammary gland is crucial for reproduction in mammals.
Development of the mammary gland is unique in that most of its differentiation occurs
post-partum. In the developing breast there is a fundamental system of small ducts that
grow slowly prior to puberty. Ductal outgrowth begins during puberty in the virgin
mouse, resulting in the formation of a ductal tree that penetrates the mammary fat pad.
Extensive ductal branching and alveolar growth occurs once the mouse is pregnant. At
the end of pregnancy, the alveolar tissue terminally differentiates and the biological
process of lactation begins (Stern, 2003).
During puberty in virgin mice, AREG is highly expressed in the mammary gland.
AREG expression is associated with the developing alveolar structure found in the
epithelial cap cells and terminal end buds (TEBs) of 4-6 week old mice (Kenney et al.,
1995). AREG -/- mice developed normal but fewer TEBs that fail to penetrate the
mammary fat pad throughout the pregnancy and into lactation.

Interestingly, when

38

AREG, EGF, and TGF-were knocked-out in combination, the effects of AREG knockdown alone were enhanced and lactogenesis was further compromised. However, when
EGF or TGF- were knocked out alone, ductal growth was normal (Luetteke et al.,
1999). This suggests that EGF and TGF- play a significant role in lactation, while
AREG is the ligand responsible for pubertal ductal morphogenesis (McBryan et al.,
2008). Supporting these findings, mammary glands from EGFR knock-out (KO) mice
were transplanted in the renal capsule of virgin athymic mice, which demonstrated a lack
of ductal outgrowth (Wiesen et al., 1999). TEB outgrowth was assessed in other ErbB
family member KO models. KO of ErbB3 resulted in mice with lower ductal density and
fewer TEBs and epithelial branches (Qu et al., 2006). ErbB2 -/- mice had mammary
glands characterized by structural defects in TEBs and a slowly advancing epithelial tree
(Jackson-Fisher et al., 2004).

These data suggest that AREG promotes ductal

morphogenesis through EGFR/ErbB2 and EGFR/ErbB3 heterodimers (Jackson-Fisher et
al., 2004; Qu et al., 2006). On the contrary, Ferguson et. al. suggested that ErbB
receptors do not typically from hetero-dimers, but produce their ligand-induced homodimerization (Ferguson et al., 2000). In the case of AREG, this would suggest EGFR
homo-dimers. In another study, the mechanism by which EGFR and AREG are required
for ductal elongation was investigated.

Using tissue recombination methods from

EGFR-/-, AREG-/-, and ADAM17-/- mice it was demonstrated that EGFR is required in
the stroma and AREG and ADAM17 are required in the epithelium for the development
of the mammary gland. ADAM17-/- tissue inhibited ductal outgrowth, indicating
ADAM17 is required for the proteolytic processing of AREG. In addition, in order for
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normal development of the ductal tree to occur, crosstalk between the stroma and
epithelium is required (Sternlicht et al., 2005).
Estrogen induced proliferation in the developing mammary glands has been
shown to be mediated by paracrine AREG signaling. In the mammary gland, ER positive
cells are not highly proliferative (LaMarca and Rosen, 2007). It is this population of cells
that produce AREG, which mediates epithelial cell proliferation in a paracrine manner.
Evidence for this was observed when AREG-/- tissue from mouse mammary glands was
transplanted into cleared fat pads from mice with wild-type (WT) tissue. The AREG -/tissue was able to proliferate when grafted into the WT tissue suggesting paracrine
signaling by AREG (Ciarloni et al., 2007).
AREG is the primary regulator of EGFR in mammary gland development and
promoter of ductal morphogenesis at puberty.

In addition to playing a role in the

mammary gland, AREG has important signaling functions in other tissues. In normal
epithelial tissue, AREG is expressed during development of the embryonic lung (Schuger
et al., 1996). EGFR and AREG interactions occur in the stroma, thereby stimulating the
proliferation of nearby epithelial cells in the ducts and TEBs. Similarly, embryonic lung
branching of the epithelial trees depends on the presence of AREG, as well as the
presence of the extracellular matrix (ECM) (Schuger et al., 1996).

In addition, AREG

stimulates epithelial branching and differentiation in embryonic mouse kidney cells (Lee
et al., 1999). Furthermore, a role for AREG has been implicated in nerve regeneration,
bone formation, and blastocyst implantation (Nilsson and Kanje, 2005; Qin et al., 2005).
The important role of AREG/EGFR interactions in tissue development and
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morphogenesis is consistent with the pathological role of AREG in mediating motility
and invasion when inappropriately expressed in cancer cells.

F. AREG expression in cancer
i. AREG/Breast Cancer
Considering the functional role of AREG in the developing breast, it is of no
surprise that AREG plays a role in breast cancer. AREG’s role in breast cancer was
illuminated by the finding that expression of AREG protein was higher and more
frequent in invasive breast carcinomas than in ductal carcinomas in situ and normal
breast tissue (Salomon et al., 1995).

In a study by LeJeune et. al., 36% of 68

inflammatory breast cancers (IBCs) expressed AREG mRNA and protein as seen by
immunocytochemistry or northern and dot blot analysis. Also, AREG expression was
observed more frequently in lymph-node-positive samples than in those that were lymphnode-negative. These studies indicated that EGFR and AREG are co-expressed in 35%
of EGFR positive tumors (LeJeune et al., 1993). Of 68 infiltrating ductal carcinomas
(IDCs) and infiltrating lobular carcinomas (ILCs), 77% expressed AREG. In addition,
p53 point mutations correlated inversely with AREG expression (Qi et al., 1994). The
large difference observed in the studies by LeJeune and Qi can be explained by the use of
a monoclonal versus polyclonal AREG antibody, respectively. Another study analyzing
100 human infiltrating breast carcinomas determined AREG expression in 50% of the
samples (Panico et al., 1996). AREG protein secretion was measured in 193 primary
breast cancers by enzyme-linked immunosorbent assays (ELISAs). Through this method
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of directly quantifying AREG protein expression, 92% of the primary breast cancers
expressed AREG. AREG expression correlated with uPA and VEGF in postmenopausal
tissues and with PR in premenopausal samples, suggesting a role for AREG in
vasculogenisis and metastasis (Desruisseau et al., 2004).
Still, AREG expression has not been shown to correlate with survival. However,
AREG has been correlated with tumor grade. Lejeune et. al. and Qi et al. both determined
that AREG correlated with lymph-node-positive cancers as compared to lymph-nodenegative cancers (LeJeune et al., 1993; Qi et al., 1994). In another study, 63.3% of 84
invasive ductal breast carcinomas were found to co-express AREG and EGFR. The coexpression of these two proteins correlated with large tumor size, node involvement,
grade III, inflammatory carcinoma, and absence of ER (Ma et al., 2001). AREG positive
staining in peritumoral host cells correlated with clinical outcome. 85% of cases
expressing AREG correlated with relapse, where as only 29% of AREG negative cases
relapsed (Visscher et al., 1997).
AREG plays a role in breast cancer leading to the progression of the disease by
promoting cell proliferation, invasion, and metastasis of epithelial cells.

The

aggressiveness of tumor cells expressing AREG was suppressed by inhibiting AREG via
anti-sense cDNA in NS2T2A1 mouse mammary tumor cells, showing a reduction in
tumor formation in vivo (Ma et al., 1998).

Mechanisms proposed for AREG/EGFR-

induced cellular invasion focus on the altered expression of matrix metalloproteases
(MMPs). These proteases play a role in embryonic development and growth, while in
cancer they function in breaking down the basement membrane barrier.

In metastatic
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breast cancer cells (SKBR-3), an increase in MMP-9 expression modulates AREG
promotion of invasion (Kondapaka et al., 1997).

Additionally, expression of the

extracellular matrix metalloproteinase inducer (EMMPRIN), activator of MMP1, 2, 3,
and 9, is down-regulated in response to AREG anti-sense treatment of NS2T2A1
(Menashi et al., 2003). In a more recent study inhibition of AREG by anti-sense cDNA
in NS2T2A1 inhibited MMP-9 expression (Ma et al., 2010). Bissell and colleagues
demonstrated the existence of an autocrine loop promoting a maliganant phenotype
mediated by ADAM17. Through the use of 3D culture models of breast epithelial cells,
they targeted ADAM17/TACE via siRNA techniques. Inhibiting ADAM17 blocked
EGFR signaling induced by AREG and TGF-. (Kenny and Bissell, 2007). DNA microarray studies comparing differences in gene expression in terminal duct lobular units
(TDLUs) and hyperplastic enlarged lobular units (HELUs) showed a 10-fold up
regulation of AREG expression in HELUs. HELUs are abnormally enlarged TDLUs and
represent premalignant potential during hormone-dependent breast cancer progression
(Lee et al., 2007).

These studies identify AREG and EGFR as regulators of

metalloproteinases leading to cell invasion and metastasis.

ii. AREG in other cancers/diseases
Expression of AREG mRNA has been observed in a variety of cancers including
colon, breast, liver, prostate, pancreatic, lung, bladder, ovarian, skin, myeloma, and
squamous cell carcinoma (D'Antonio et al., 2002; Ebert et al., 1994; Fontanini et al.,
1998; Mahtouk et al., 2005; Salomon et al., 1995; Sehgal et al., 1994; Tsai et al., 2006;
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Yamane et al., 2008).

Interestingly, AREG expression is also correlated with

inflammatory disease: for example, rheumatoid arthritis, ulcerative colitis, and Chron’s
disease (Nishimura et al., 2008; Yamane et al., 2008). AREG expression in invasive
tumors was correlated with locally advanced inflammatory carcinoma (Ma et al., 2001).

iii. AREG and treatment of cancers
EGFR and AREG are co-expressed in approximately 15% of invasive breast
carcinomas (Ma et al., 2001). In phase II clinical trials, the two main classes of EGFR
inhibitors, small molecule EGFR TKIs and monoclonal antibodies, lead to tumor
regression in 10-20% of NSCLC patients (Fukuoka et al., 2003; Kris et al., 2003). In
lung cancer cells expressing WT EGFR, gefitinib and cetuximab showed higher efficacy
in cells producing high levels of AREG (>20 pmol/L) relative to cells producing low
levels of AREG (<20pmol/L). This effect is thought to occur by cell cycle arrest and
inhibition of ERK1/2 signaling. This study suggests that in lung cancer patients
expressing WT EGFR, AREG may be a predictor for the use of EGFR-targeted therapies
to promote stable disease (Khambata-Ford et al., 2007; Yonesaka et al., 2008).
Additionally, in metastatic colorectal cancers, high concentrations of AREG in serum has
been correlated with longer progression-free survival as compared to patients with low
serum levels of AREG in response to treatment with cetuximab (Khambata-Ford et al.,
2007). On the contrary, in MCF7 breast cancer cells, AREG has been shown to be a
factor in development of resistance to the platinum based chemotherapeutic drug,
Cisplatin. The correlation between Cisplatin resistance, examined by MTT assays, in a
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panel of breast cancer and lung cancer cells lines demonstrated that the expression of
AREG correlates with resistance only in breast cancer and not in lung cancer (Eckstein et
al., 2008).

1.3 Invasion
A. EGFR and AREG
Normal cells undergo physiological processes such as embryonic morphogenesis,
wound healing, and immune cell trafficking which require mechanisms of cell migration
and invasion. Neoplastic cells use these mechanisms to promote cell entry into the
lymphatic and blood vessels, thus promoting growth in distant organs (Reviewed by
(Friedl and Wolf, 2003)). Invasion is described as “penetration of tissue barriers, such as
basement membrane and interstitial stroma, by cells” (Friedl and Wolf, 2003).
There are four main activities that are associated with the invasive phenotype:
cell-cell adhesion, cell-matrix interactions, migration, and proteolysis (Mareel and Leroy,
2003). During invasion, cell-cell adhesions can be weakened (Yamazaki et al., 2005). Ecadherin is one such adhesion molecule that acts as a tumor suppressor. In some
instances, loss of E-cadherin stimulates migration and cellular invasion (Bracke et al.,
1997; Handschuh et al., 1999). The ECM provides a barrier, substrate, and signal for cell
invasion by providing motility factors and regulating survival (Mareel and Leroy, 2003).
Cell-matrix interactions occur through molecules such as: integrins; transducers of
signals regulating anchorage independent growth, and FAK, a NRTK regulating actin
cytoskeleton signaling (Parsons et al., 2000). In order for the cells to invade the matrix,
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cells must utilize locomotive factors and migrate (Mareel and Leroy, 2003). Src and
PI3K pathways have been demonstrated to be necessary for cell invasion (Empereur et
al., 1997). Lastly, proteolysis, a process involving the cleavage of proenzymes, promotes
the breakdown of the ECM creating routes for invasive cells to migrate. Invasive cells
make MMPs, urokinase-type plasminogen activators, and cysteineproteinases to aid in
proteolysis (Mareel and Leroy, 2003).
EGFR over expression was suggested to play a role in tumor progression,
however EGFR over expression did not correlate with proliferation; it correlated with
progression to cellular invasion.

This has been observed in glioblastomas, bladder

carcinomas, and gastric carcinomas. Up-regulated EGFR is present in invading brain
tumors as compared to non-invasive glimoas (Libermann et al., 1984; Schlegel et al.,
1994). In bladder carcinomas, Neal et. al. found EGFR expression to correlate with
tumor progression, poor differentiation, and invasion (Neal et al., 1985). Additionally, in
gastric tumors non-invading tumors did not express EGFR whereas nearly one third of
invasive tumors over expressed EGFR (Kitadai et al., 2000).
The mechanisms proposed for over expressed EGFR’s promotion of cell invasion
are associated with cell-cell adhesion, cell-matrix interactions, migration, and proteolysis.
AREG-induced EGFR has been reported to up-regulate MMP-2 and -9 (Kondapaka et al.,
1997; Ma et al., 2010; Menashi et al., 2003). Expression of MMPs alters the ECM to
allow the passage of cells to invade the stroma, intravasate a lymph or vascular channel
where the cell can circulate and extravasate into tissues at distant sites (Stetler-Stevenson
and Yu, 2001).

GPCR ligands, such as lysophosphatidic acid (LPA), promote the
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proteolytic processing of ligands like AREG, via TACE, leading to EGFR
phosphorylation

in

kidney

and

bladder

cancer

cells
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vitro

via

ADAM

metalloproteinases, more specifically by ADAM-10, -15, and -17 (Gschwind et al., 2003;
Schafer et al., 2004). EGFR transactivation by LPA stimulation promotes cell invasion
(Schafer et al., 2004). In addition to LPA, the GPCR ligand gastrin releasing peptide
(GRP), induces EGFR phosphorylation followed by src activation of TACE and cotranslocation to the cell surface where TACE initiates the subsequent release of AREG,
thus facilitating cell invasion in head and neck squamous cell carcinomas (Zhang et al.,
2004).
EGF activation of EGFR can lead to cell motility and invasion in renal
carcinomas, and squamous cell carcinomas (Price et al., 1996; Shibata et al., 1996). In
another study examining MDA-MB 468 breast cancer cells, DU-145 prostate cancer
cells, KB oral carcinomas, and NIH3T3 cells over expressing EGFR, EGF-induced dephosphorylation and reduced kinase activity of FAK, ultimately inducing cancer
phenotypes: cell motility, invasion, and metastasis (Lu et al., 2001). Aside from EGFR
signaling events inducing the expression of genes that promote invasion, it is
hypothesized that EGFR can be activated by matrix components. This was most clearly
seen by the expression of decorin, a matrix component that binds to fibrillar collagen
(Iozzo et al., 1999).
Additional mechanisms relate to EGFR signaling observed during normal
physiological activities. Activated EGFR interacts with PLC-. PLC- promotes cell
motility through the hydrolysis of PIP2 allowing for cytoskeletal rearrangement (Chen et
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al., 1994). Treatment with PLC- inhibitors prevented invasion of prostate tumor in
mice, corroborating PLC-’s role in tumor invasion in the presence of EGFR over
expression (Turner et al., 1997).
In our lab’s recent work, an AREG/EGFR autocrine loop has been shown to
stimulate cell motility and invasion (Willmarth and Ethier, 2006).

Whether AREG

stimulation of EGFR or EGFR over expression itself are the causal effects of cellular
invasion remains to be elucidated.

B. Other factors promoting invasion
i. RHOB
Ras-homologous (Rho) small guanosine triphosphatases (GTPases) regulate a
variety of cellular functions, such as: organization of the cytoskeleton, cell-cycle
progression, cell-cell contact, cell polarity, migration, adhesion, cell morphology, genetranscription, and cell transformation (Bishop and Hall, 2000). As a family member of
small G proteins, Rho regulates these cellular processes by working as a molecular
switch, rotating between GDP- and GTP-bound states (Boguski and McCormick, 1993).
Rho-GTP can effectively interact with an effector molecule to initiate a signaling event
specific to the target molecule (Bishop and Hall, 2000). In an inactive state, Rho-GDP is
associated with guanosine nucleotide dissociation inhibitor (RhoGDI), thereby inhibiting
the spontaneous GDP to GTP exchange (Bishop and Hall, 2000).
RhoB exhibits several characteristics that distinguishes it from its other family
members. For example, RhoB is localized to the early endosomes and nuclear membrane
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(Michaelson et al., 2001), it promotes intracellular trafficking of cytokine receptors (i.e.
EGFR) (Gample, A. 1999, Curr Bio), and it has a rapid response to growth factors (i.e.
EGF, TGF-B) and genotoxic stress. These qualities suggest RhoB involvement in cancer
progression.
While Rho protein expression has been correlated with disease progression, RhoB
appears to function as a tumor suppressor. Loss or reduction of RhoB expression has
been observed in the progression of lung cancer, head and neck squamous cell carcinoma,
and ovarian cancer (Adnane et al., 2002; Couderc et al., 2008; Mazieres et al., 2004). On
the contrary, Fritz et. al. demonstrated an over expression of RhoB protein in normal and
tumorigenic tissues (Fritz et al., 2002). In NIH3T3 cells, transfected with RhoB and a
serum response element, cell transformation, invasion, and metastasis was suppressed.
Experiments aimed to identify RhoB’s tumor suppressor activity suggest that RhoB
negatively regulates the Ras/PI3K/Akt tumor survival pathway (Jiang et al., 2004).

ii. DKK1
Canonical Wnt signaling is occurs when a Wnt family member binds to a cell
surface receptor Frizzled (FRZ). FRZ interacts with a cell surface molecule lipoproteinreceptor related protein (LRP) and axin. Subsequently, disheveled (DSH) proteins are
activated resulting in a Wnt/FRZ/DSH/LRP/axin complex. The Wnt/FRZ/DSH/LRP/axin
complex inhibits the formation of an axin/GSK-3/APC complex responsible for inhibiting
B-catenin degradation. This signaling ultimately results in an increase in B-catenin
levels.

49

Dickkopf-1 (dkk-1), one of four family members of Wnt inhibitors, is a secreted
protein involved in embryogenesis and Wnt signaling (Glinka et al., 1998). It was first
isolated from Xenopus (amphibian) cDNAs that complemented in the formation of a
secondary axis during embryogenesis (Glinka et al., 1998). Dkk-1 is composed of 259
AA and contains a signal sequence and two cystenine-rich domains. In the search for
Erb3 ligands, a 35 kDa band was identified by silver staining analysis representing the
human dkk-1.

Northern blot analysis in fetal and adult tissues identified dkk-1

expression in fetal, kidney, liver, and brain tissue, as well as in adult placenta and
prostate tissue (Fedi et al., 1999). In the amphibian embryos, dkk-1 was found to be
required for head formation by antagonizing Wnt signaling (Glinka et al., 1998).
Biochemical approaches determined that human dkk-1 disrupts Wnt signaling and acts
up-stream of B-catenin stabilization, which is associated with the morphological effects
of transforming Wnts (Fedi et al., 1999). Mechanistically, Dkk-1 inhibits Wnt signaling
by binding to the LRP5/6. Wnt/B-catenin signaling is blocked by LRP5/6 (Mao et al.,
2001).
Knockout of Dkk-1 in mice resulted in mice lacking anterior heads and forelimb
malformations (Mukhopadhyay et al., 2001). In cancer, levels of secreted Dkk-1 are low,
resulting in an accumulation of nuclear -catenin. Expression of recombinant dkk-1 in
MCF-7 breast cancer cells down-regulated macrophage induced invasion in a dosedependent manner. The decrease in the invasive phenotype was independent of cell
proliferation and cellular metabolism (Pukrop et al., 2006).
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IV. SUM-149 Breast Cancer Cells
The SUM series of cell lines were developed from patients with breast cancer in
our laboratory. SUM-149 cells were isolated from a patient with aggressive, premenopausal, locally advanced inflammatory ductal carcinoma. The patient failed all
treatment with chemotherapy, radiation, and surgery. The cells are ER- and PR- and
express low levels of ErbB2 and ErbB3. Additionally, SUM-149 cells have a BRCA1
mutation, have increased levels of cyclin E, and are basal-type (Elstrodt et al., 2006).
Cyclin E is a cyclin expressed during G1 phase and is essential for transitioning through
the cell cycle to S phase. SUM-149 cells due to a mutation in hCdc4, a F-box protein,
have stabilized expression of cyclin E (Willmarth et al., 2004).
SUM-149 cells are used frequently as they are one of three inflammatory breast
cancer cell lines in existence. SUM-149 cells have been shown to be able to grow in soft
agar and invade a matrigel matrix in vitro (Ignatoski and Ethier, 1999). Moreover, SUM149 cells express high levels of RhoA and RhoC, E-cadherin, NF-B and caveolins-1 and
-2 (Dong et al., 2007; Hoffmeyer et al., 2005; Pan et al., 2003; Pan et al., 2002; Van den
Eynden et al., 2006; van Golen et al., 2002; van Golen et al., 2000).
Our lab found that SUM-149 cells over express constitutively active EGFR
without gene amplification.

They are EGF independent for growth; however, they

require EGFR for proliferation. This was based on the observation that after treatment of
the cells with EGFR inhibitor CI-1033, cells no longer proliferated (Rao et al., 2000).
AREG was detected in SUM-149 cells by molecular cloning techniques. RNA
was isolated, reverse transcribed into cDNA, and cloned into retroviral vectors that were
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subsequently infected in MCF-10 cells growing in the absence of exogenous growth
factors (Berquin et al., 2005). MCF10A cells are normal human mammary epithelial
cells that spontaneously immortalized (Soule et al., 1990). cDNA was isolated from
emerging colonies and analyzed by PCR. Subsequent analysis demonstrated that the
growth of SUM-149 cells is regulated predominately by AREG (Willmarth and Ethier,
2006).
SUM-149 cells express a self-sustaining AREG/EGFR autocrine loop and can
activate EGFR in a juxtacrine fashion. They over express AREG mRNA and protein and
are more invasive and motile than MCF10A cells growing in the presence of EGF
(Willmarth and Ethier, 2006). In addition, SUM-149 cells show an increase in the steady
state levels of EGFR that localizes to the plasma membrane (Willmarth and Ethier,
2008). Previously it was observed that SUM149 cells have constitutive NF-B activity
(Pan et al., 2003). The activation of EGFR by AREG then generates a positive feedback
loop involving IL-1 and NF-B (Streicher et al., 2007).
The over expression of AREG at the mRNA and protein level, and the presence of
a functional AREG/EGFR autocrine loop that is maintaining EGFR activity and
contributing to SUM-149 cellular invasion and motility makes these cells a useful model
for testing the effect of AREG knock-down. We predicted that by knocking-down AREG
we would stop or slow cell proliferation, motility, and invasion. By using SUM-149 and
MCF10A cells as our cell models we aimed to examine the effect of AREG knock-down
on the cancer-associated phenotypes in order to better understand the role of AREG in
cancer progression.
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CHAPTER 2
MATERIALS AND METHODS

2.1 Reagents and Antibodies—The antibodies used were mouse monoclonal, anti-EGFR
antibody MAB108 from a mouse hybridoma (gift from Julie Boerner, Karmanos Cancer
Institute) for detecting EGFR in immunofluorescence experiments and, mouse
monoclonal anti-EGFR antibody clone 31G7 (Zymed Laboratories, Inc., San Francisco,
CA, USA) to detect EGFR, anti-EGFR human (mouse) antibody clone 225 (C225) (EMD
Chemicals, Gibbstown, NJ, USA) to block ligand binding to EGFR, goat polyclonal antiAREG antibody (R&D Systems) to detect AREG and neutralize AREG, mouse
monoclonal antibody PY-20 (EMD Chemicals, Gibbstown, NJ, USA) to detect EGFR
tyrosine phosphorylation, B-Actin (Sigma-Aldrich, St. Louis, MS) was used as a loading
control, rabbit polyclonal anti-RhoB antibody (Cell Signaling Technologies, Danvers,
MA, USA) to detect RhoB, goat polyclonal anti-EGF and mouse monoclonal anti-EPGN
antibodies (R&D systems, Minneapolis, MN, USA) to neutralize EGF and EPGN,
Phospho-specific antibodies Y845, 992, 1068, 1086, and 1148 (Cell Signaling
Technologies, Danvers, MA, USA) to detect EGFR tyrosine phosphorylation, IgG mouse
and goat (R&D systems, Minneapolis, MN, USA) to detect non-specific effects on cell
growth. 0.5 μmol/L Gefitinib/Iressa (AstraZeneca Pharmaceuticals, Wilmington, DE,
USA).
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2.2 Cell Culture—SUM149 cells were maintained in Ham's F-12 medium with 5% fetal
bovine serum, 5 μg/ml insulin, 2 μg/ml hydrocortisone, 5 μg/ml gentamicin, and 2.5
μg/ml fungizone (5%IH). SUM-149sh4, SUM-149shPld, and SUM-149shNS cells were
maintained in 5%IH plus 1ug/ml puromycin. The serum-free base medium for MCF10A
and MCF10A+AREG cells was SFIH (Ham's F-12 with 1 μg/ml hydrocortisone, 1 mg/ml
bovine serum albumin, 10 mm Hepes, 5 mm ethanolamine, 5 μg/ml transferrin, 10 nm
triiodothyronine, 50 nm sodium selenate, 5 μg/ml gentamicin, 2.5 μg/ml fungizone, and 5
μg/ml insulin), and MCF10A cells required 10 ng/ml EGF (SFIHE). MCF10A + AREG
cells were MCF10A cells grown in SFIH medium with 20 ng/ml exogenous AREG
(SFIHA), which was found previously to be the biologically equivalent concentration to
EGF for these cells (Berquin et al., 2005). All cells were maintained in a humidified
incubator at 37 °C and 10% CO2.
2.3 Lenti-AREG shRNA infection—Knock-down of AREG expression was performed
using Mission TRC human shRNA clone sets (OpenBiosystems, Huntsville, AL, USA).
sh1:CCGGGAACCACAAATACCTGGCTATCTCGAGATAGCCAGGTATTTGTGGT
TCTTTTTG;sh2:CCGGGCCGACTATGACTACTCAGAACTCGAGTTCTGAGTAGT
CATAGTCGGCTTTTTG;sh3:CCGGCCTGGCTATATTGTCGATGATCTCGAGATC
ATCGACAATATAGCCAGGTTTTTG;sh4:CCGGGAACGAAAGAAACTTCGACAA
CTCGAGTTGTCGAAGTTTCTTTCGTTCTTTTTG;sh5:CCGGCACTGCCAAGTCAT
AGCCATACTCGAGTATGGCTATGACTTGGCAGTGTTTTTG.

Lentivirus

was

produced by transfecting human embryonic kidney (HEK293) cells at 80% confluence in
10%DMEM without antibiotics and infecting HEK293 cells with packaging plasmids:
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350ng mDLg/pRRE, 350ng pRSV-Rev, 250ng MD2.G, and 1ug of each pLKO.1 AREG
shRNA plasmid using FuGENE (according to manufacture’s protocol).

Cells were

incubated for 12-14 hrs at 37°C at which time media was changed to 10%DMEM with
antibiotics. Virus was harvested 48 and 72 hrs post infection, centrifuged at 1500 rpm for
5 min and filtered through a .45micron filter. Recipient cells were seeded at 1x106 cells
per 10 cm dish, treated with 8ug/ml polybrene and infected with 48 hr virus harvested
from HEK293 cells. Cells were incubated for 12 hrs and new media with 1ug/ml
puromycin was added for 2 weeks before functional assays, and 4-10 days before RNA
extraction was performed.

2.4 Real-time RT-PCR—Total RNA was isolated from subconfluent cells using an
RNeasy kit (Qiagen, Valenica, CA, USA) and reverse-transcribed into cDNA using the
Superscript III First-Strand Synthesis kit (Invitrogen, Calsbad, CA, USA). Primer sets
specific to approximately 100bp sequences of target genes and a control gene (PUM1)
used were designed and synthesized by Invitrogen. Primer sets were: AREG
F5’GTGGTGCTGTCGCTCTTGATA3’ R5’ACTCACAGGGGAAATCTCACT3’ BTC
F5’TTCACTGTGTGGTGGCAGAT3’

R5’CCTTTCCGCTTTGATTGTGT3’

EGF

F5’CGCAGGAAATGGGAATTCTA3’ R5’TCCACCACCAATTGCTCATA3’ TGFA
F5’TCGCTCTGGGTATTGTGTTG3’ R5’GGGAATCTGGGCAGTCATTA3’ HB-EGF
F5’GGCAGATCTGGACCTTTTGA3’

R5’CCCCTTGCCTTTCTTCTTTC3’

EPGN
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F5’CCCAGCAAGCTGACAACATA3’ R5’CTCATGGTGGAATGCACAAG3’ EREG
F5’CTGCCTGGGTTTCCATCTTCT3’ R5’GCCATTCATGTCAGAGCTACACT3’
RHOB F5’ATCCCCGAGAAGTGGGTCC3’ R5’CGAGGTAGTCGTAGGCTTGGA3’
CNTN1 F5’GTGGCACTTACTTGGAGCC3’ R5’GGGGGATCTGTCTTTGCATCTT3’
HEY1 F5’TATCGGAGTTTGGGATTTCG3’ R5’AGATGCGAAACCAGTCGAAC3’
HES7

F5’CGGGATCGAGCTGAGAATAGG3’

R5’GCGAACTCCAATATCTCCGCTT3’. Real-time RT–PCR was performed in 25 ul
reactions using 96-well plates, 100 to 200 ng cDNA, and the FastStart SYBR Green
Master Mix (Roche Diagnostics, Mannheim, Germany). The reactions were done in
replicates of three using the Bio-rad iQ5 real-time PCR machine (Bio-Rad Laboratories,
Hercules, CA). Calculation of the ΔΔCT values was performed as previously described
(Livak and Schmittgen, 2001). Briefly, for each cell line, the average number of cycles
for PUM1 control primer reactions to reach threshold fluorescence was calculated and
subtracted from the average number of cycles for the test primer reactions to reach
threshold fluorescence, the differences are raised to the power of -2 and then the negative
inverse was taken.

2.5 Immunoblotting— Cells were grown to 80% confluence in their normal growth media
and lysed in a buffer containing 20 mM Tris-HCl (pH 8.0), 137 mM NaCl, 1%NP40,
10% glycerol, 1 mM Na3VO4, 1 mM phenylmethylsulfonyl fluoride, 1% aprotinin, and
20 μg/ml leupeptin for 10 minutes. Cells were scraped and spun down to remove cell
material. Protein concentrations were equalized using the Bradford method. For whole
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cell lysates, Laemmli sample buffer was added and the samples were boiled. Western
blotting was performed as previously described (Kumar-Sinha et al., 2003). 50-500ng of
protein from whole cell lysates was loaded onto 15% SDS-polyacrylamide gels for
AREG detection, and for EGFR detection lysates were loaded onto 7.5% SDSpolyacrylamide gels. After transferring proteins to polyvinylidene difluoride membranes,
blots were probed with required antibodies: anti-EGFR antibody 31G7 (Zymed
Laboratories), phosphor-tyrosine antibody P-Tyr (EMD Chemicals), anti-AREG antibody
AF262 (R & D Systems), phospho-tyrosine specific antibodies (Cell Signaling
Technologies)

or

anti-B-Actin

(Sigma-Aldrich)

and

visualized

by

enzymatic

chemiluminescence (Pierce, Thermos Fisher Scientific, Waltham, MA).
2.6 Enzyme-linked Immunosorbent Assay (ELISA)—Twenty-four hour conditioned
medium was obtained from cells grown in 6-well plates. An AREG DuoSet ELISA
(R&D systems, Minneapolis, MN, USA), with an AREG antibody specific to the
extracellular domain of AREG was used to measure AREG medium concentration. High
binding ELISA plates were coated with 3 μg/ml AREG antibody in sterile phosphatebuffered saline (PBS) overnight at room temperature. Absorbance was measured on a
VERSAmax microplate reader (Molecular Devices Corp., Sunnyvale, CA, USA). Cells
were lysed, and nuclei were counted with a Z1 Coulter Counter (Beckman Coulter, Brea,
CA, USA) for normalization. Samples were done in triplicate.
2.7 Cell Proliferation Assays—Cells were seeded on day 0 in 6-well plates at 1.0×104
cells/well. Either 1 μg/ml AREG Ab, 1 μg/ml EGFR Ab, 1 μg/ml EGF Ab, 1 μg/ml
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EPGN Ab, 1 μg/ml IgG Mouse Ab, and 1 μg/ml IgG Goat Ab, or 0.5 μmol/L Iressa was
added daily. After 7 days of treatment, plates were washed with PBS three times and
agitated on a rocker table with 0.5 ml of a Hepes/MgCl2 buffer (0.01 m Hepes and 0.015
m MgCl2) for 5 min. Cells were then lysed for 10 min using a Bretol (ethyl
hexadecyldimethylammonium) solution, and the nuclei were counted using a Z1 Coulter
Counter (Beckman Coulter, Brea, CA, USA). Day 1 cells were counted for seeding
efficiency. All experiments were done in triplicate.
2.8 Cell Invasion Assay—Matrigel invasion chambers (BD Biosciences, San Jose, CA,
USA) were rehydrated with Dulbecco's modified Eagle's medium for 1 h in a 37°C
incubator. 2.5 × 105 of MCF10A cells in SFIHE medium and SUM149, SUM-149sh4,
SUM-149shPld, SUM-149shNS cells in SFIH medium were added to the upper chamber
of both control and rehydrated Matrigel invasion chambers. 5% fetal bovine serum was
added to media in the bottom chamber as a chemoattractant. After 24 h, membranes were
fixed and stained using the Hema 3 Staining System (Thermo Fisher Scientific, Waltham,
Massachusetts, USA). Membranes were allowed to dry and then were placed onto slides
for visualization. Cells on Matrigel membranes were counted from six microscopic fields
after 24 h. Percentage of invasion was calculated by dividing the mean number of cells
on the invasion membranes by the number of cells seeded for each cell line. Experiments
were repeated three times.
2.9 Soft Agar Assay—A bottom layer of 1:1 Ham's F-12 serum-free medium to 1%
agarose was poured and allowed to solidify. A 1-mL suspension of 1.0 × 105 cells in a
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0.3% agarose solution was plated into six-well plates and fed once a week by adding 3mL
medium on top of the soft agar. Cells were then counted at weeks three and four with
GelCount automated mammary colony counter (Oxford Optronix, Oxford, UK).

2.10 In vitro Mammosphere assay—For the in vitro mammosphere assay, cells were
grown in a serum-free mammary epithelial growth medium (MEBM Basal Medium,
Lonza, Walkersville, MD, USA) supplemented with B27 (Invitrogen, Carlsbad, CA,
USA) 1μg/ml hydrocortisone, 5μg/ml insulin, 5μg/ml β-mercaptoethanol, and 10ng/ml
epidermal growth factor; 10,000 cells were plated on a six-well ultra low attachment plate
(Corning Inc., Acton, MA, USA) and 1ml of medium was added every 3 days. After 7–10
days, the mammospheres were moved to adhering dishes, allowed to attach with 2% FBS,
stained with 1X crystal violet for 1 min, washed, and counted after 2-4 days.

2.11 Immunofluorescence assays —Approximately 1×105 SUM-149, SUM-149sh4,
SUM-149shPld, and SUM-149shNS cells were seeded on coverslips and given 5%IH,
5%IH+10ng/ml EGF, of 5%IH+20ng/ml AREG for 24hours. The next day, cells were
washed 3 times with ice cold PBS, fixed in 4% para-formaldehyde for 20 min at room
temperature, washed 3 times in PBS and then permeabilized with ice cold 0.1% Triton-X
in PBS for 2 min. Cells were washed 3 times and then blocked for 1 h in 20% Goat
Serum. A 1:1000 dilution of 2 μg/μl anti-EGFR antibody MAB108 was incubated with
cells for 1 h. Cells were washed 3 times and incubated for 1 h with an Alexa488conjugated anti-mouse secondary antibody (Molecular Probes, Invitrogen) at 1:1000
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dilution. Cells were then washed 3 times with PBS and once more with distilled water to
remove salt. ProLong gold with DAPI was used as a mounting reagent (Molecular
Probes, Invitrogen) and coverslips were put on slides for microscopy. Pictures were
taken with a 65× oil lens on a Zeiss LSM-310 Laser Scanning Confocal Microscope
at the Wayne State University Confocal Imaging Facility.

2.12 Illumina microarray analysis— RNA was isolated from SUM-149, SUM149sh4,
SUM-149shPld,

SUM-149shNS,

MCF10A,

MCF10A+AREG,

MCF10A-EGF,

MCF10A-AREG cells in triplicate. Quantity measurement of all RNA samples was
measured by analysis with the NanoDrop 1000 (Agilent Technologies, Waldbronn,
Germany). Expression levels for each cell line were determined by microarray analyses
using the Illumina human Ref12v3 chip (Illumina, San Diego, CA, USA). Data were
processed for quality control and normalized across compared arrays by quantile
normalization. Data were exported from GenomeStudio after performing the needed
quality control checks and uploaded into GeneSpring. The data were then quantile
normalized, transformed to median baseline, and analyzed using Ingenuity Pathway
analysis. Using an un-paired T-test genes were found to be significantly different in
expression at the p<0.05 level.

An additional statistical test, Rank-Prod was also

performed which identified genes that were significantly different at the p< 0.05 level.
The genes described were present in both gene sets.

Genes identified using these

statistical tests were imported into the Ingenuity Knowledge Base for further analysis.
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The raw data of the SUM-149 and MCF10A microarray analysis have been deposited in
the GEO database GSE26079 and GSE26264, respectively.
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CHAPTER 3
KNOCK-DOWN OF AMPHIREGULIN INHIBIITS CELLULAR
INVASION IN INFLAMMATORY BREAST CANCER
3.1 Introduction
The epidermal growth factor receptor (EGFR) is a transmembrane protein
belonging to the ErbB tyrosine kinase family. EGFR is activated following binding of
one of a number of EGFR ligands, which include epidermal growth factor (EGF),
amphiregulin

(AREG),

betacellulin

(BTC),

heparin-binding

EGF

(HB-EGF),

transforming growth factor alpha (TGF-a), epiregulin (EREG), and epigen (EPGN)
(Olayioye et al., 2000). Ligand binding to the extracellular domain of EGFR initiates
activation of receptor dimers resulting in phosphorylation of the C-terminal tail, and
subsequent down stream signaling. De-regulation of EGFR expression or signaling has
been implicated in cancer progression. In fact, approximately 30% of breast cancers over
express EGFR, which correlates with poor prognosis (Nicholson et al., 2001; Tsutsui et
al., 2002).
AREG is a heparin binding growth factor that binds EGFR (Cook et al., 1991). It
was first isolated from the conditioned medium of MCF-7 breast cancer cells following
treatment with a tumor promoter, phorbol 12-myristate 13-acetate (PMA) (Shoyab et al.,
1988).

AREG was named for its ability to stimulate the proliferation of human

fibroblasts and keratinocytes as well as tumor cells, and its ability to inhibit the
proliferation of some carcinoma cell lines in culture (Shoyab et al., 1988). Later studies
showed that AREG is synthesized as a 252 amino acid transmembrane precursor that
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requires proteolytic cleavage for secretion.

Cleavage results in two mature soluble

protein forms consisting of either 78 or 84 amino acids and ranging from 19-21-kDa in
molecular weight (Plowman et al., 1990; Shoyab et al., 1989).

Post-translastional

modifications of pro-AREG produces a major soluble 43-kDa form, 28-, 26-, 16-kDa
membrane anchored forms, and soluble 21-, 19-, and 9-kDa forms (Brown et al., 1998) .
AREG acts as an autocrine growth factor in human urothelial cells, normal human
keratinocytes, and human lung bronchial epithelial cells (Kansra et al., 2004; Tsao et al.,
1996; Varley et al., 2005; Willmarth and Ethier, 2006). During development in the
mouse mammary gland, AREG has been shown to play an important role in terminal end
bud formation and ductal elongation (Ciarloni et al., 2007; Luetteke et al., 1999). In
addition, expression of AREG mRNA has been observed in a variety of cancers including
colon, breast, liver, prostate, pancreatic, lung, bladder, ovarian, skin, myeloma, and
squamous cell carcinoma (D'Antonio et al., 2002; Ebert et al., 1994; Fontanini et al.,
1998; Mahtouk et al., 2005; Salomon et al., 1995b; Sehgal et al., 1994; Tsai et al., 2006).
SUM-149 breast cancer cells were isolated from a patient with triple negative,
inflammatory breast cancer whose disease progressed through chemotherapy. Our lab
found that SUM-149 cells over express constitutively active EGFR, are EGF independent
for growth, and over express AREG mRNA and protein. The EGF-independent growth of
SUM-149 cells is regulated predominately by AREG (Willmarth and Ethier, 2006).
Previously, our lab has shown that in SUM-149 cells AREG functions through a
self-sustaining AREG/EGFR autocrine loop. In this loop, AREG stimulation of EGFR
results in AREG transcription and secretion allowing for AREG to signal EGFR
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continuously. More recently we have shown that AREG activation of EGFR results in an
increase in the steady state levels of EGFR and accumulation of EGFR at the cell surface
(Willmarth et al., 2009; Willmarth and Ethier, 2006). Consistent with our previous
findings, Baldys et. al. (Baldys et al., 2009) showed that AREG promotes the recycling of
EGFR to the plasma membrane. Still the role of AREG in cancer has not been fully
elucidated. In this report we describe knock-down of AREG expression using shRNA
techniques to analyze the cancer-associated phenotypes and to examine the genes
regulated by AREG that contribute to these phenotypes.
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3.2 Results
AREG Knock-down Slows Proliferation of SUM-149 cells.
Our lab has previously shown that SUM-149 breast cancer cells are dependent on
EGFR activation for proliferation and depend on a self-sustaining AREG/EGFR
autocrine loop promoting proliferation (Willmarth and Ethier, 2006). Given that AREG is
primarily responsible for EGFR activation, we wanted to investigate the effects of AREG
knock-down on these phenotypes in the SUM-149 cells. Using five pLKO.1 shRNA
constructs specific to AREG, and a non-silencing (SUM-149shNS) vector from
OpenBiosystems, we knocked-down AREG expression in the SUM-149 cells. Among the
five constructs tested, three constructs induced the highest level of AREG knock-down,
yielding approximately 15 to 60-fold reduction in AREG mRNA levels.

The sh4

construct induced the most dramatic knock-down resulting in a 40-60-fold decrease in
AREG mRNA expression, as determined by real-time RT-PCR analysis (Fig. 3.1A). In
attempt to achieve an even further fold-change in AREG knock-down, the three best
constructs (viruses sh2, sh3, and sh4) were pooled (shPld) and used to infect the SUM149 cells. By real-time RT-PCR, we did not observe any additional AREG knock-down
by pooling the three constructs as compared to infection with the sh4 virus alone (Fig.
3.1B). As a result, all additional experiments were performed using SUM-149sh4 and
SUM-149shPld cells, as compared to SUM-149shNS cells, which were infected with a
non-silencing control shRNA.
To test the effects of shRNA on AREG protein expression, we quantified the
amount of AREG secreted into the conditioned media by an enzyme-linked
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immunosorbent assay (ELISA). Conditioned media was removed from 80% confluent
cells, cells were counted, and the media was analyzed using an AREG specific ELISA kit
(R&D Systems). Secreted AREG was un-detectable in the conditioned media of the
knock-down cells, while the SUM-149 parental and SUM-149shNS controls secreted
approximately 100pg/ml AREG/100,000 cells over 24hrs (Fig. 3.1C). To measure the
presence of cellular AREG protein, western analysis was performed with the parental and
knock-down cells. Western blot analysis demonstrated a dramatic decrease in each of the
AREG isoforms (Fig. 3.1D). However, a faint band representing the 43 kDa AREG
isoform was detected in the SUM-149sh4 and SUM-149shPld cells.

Next, we

investigated the rate of proliferation in the control cells and each of the knock-down
populations. Growth assays following infection with the sh2, sh3, and sh4 and treatment
with the selecting antibiotic, puromycin, resulted in the greatest decrease in cell
proliferation relative to the SUM-149shNS control (Fig. 3.2A). Doubling times (DT)
were determined by counting cells at five time points over a 94 hr period. SUM-149 and
the SUM-149shNS cells had a DT of 27 and 29 hrs, respectively, while SUM-149sh4 and
SUM-149shPld cells had DTs of 36 and 42 hrs, respectively (Fig. 3.2B). These results
indicate that a 40-60-fold knock-down of AREG reduced, but did not completely block
proliferation of SUM-149 cells.
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Figure 3.1

AREG Knock-down in SUM-149 cells
SUM-149 cells were stably infected with various AREG shRNA lentiviral expression
constructs. Levels of AREG mRNA expression in cells infected with each individual
construct and the combined sh2, sh3, sh4 constructs (shPld) was measured by real-time
RT-PCR (A&B). SUM-149 mRNA expression was set to one. Secreted AREG was
measured by ELISA (B). Conditioned media was harvested after 24 hours from the SUM149, SUM-149sh4, SUM-149shPld, and SUM-149shNS cells. The cells were counted and
the concentration of AREG was normalized to cell number. AREG protein expression in
the whole cell was measured by western blot (D).
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Figure 3.2

AREG knock-down decreases the rate of proliferation in SUM-149 cells
(A) Infected cells were treated with 1ug/ml puromycin 12 hours post-infection (Day1)
and counted at days 4, 7, and 10. B) Cells at low passage following shRNA infection
were seeded at 1x104 cells per well and counted at approximately 24 hour intervals for 94
hours, and doubling times were calculated. Error bars represent the standard deviation of
three replicates in the experiment.
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Continued proliferation of AREG knock-down cells is EGFR dependent
Despite the high levels of AREG knock-down, SUM-149sh4 and SUM-149shPld
cells continued to proliferate, although at a slower rate than the parental cells. To address
the continued proliferation of the AREG knock-down cells, we first investigated the
status of EGFR in these cells. We performed EGFR western blot analysis on the parental
and knock-down cells. Results shown in figure 3.3A demonstrated an increase in steadystate EGFR protein levels in the AREG knock-down cells compared to SUM-149 and
SUM-149shNS (Fig. 3.3A). Consistent with the increase in EGFR protein expression we
observed

a

further

accumulation

of

EGFR

to

the

plasma

membrane

by

immunofluorescence in the AREG knock-down cells (Fig. 3.4). Western analysis of
specific EGFR tyrosine phosphorylation sites including, Y845 (phosphorylated by src),
and autophosphorylation sites Y992, Y1068, Y1086, and Y1148 indicated that EGFR
remained active in the knock-down cells (Fig. 3.3B), which is consistent with continued
slower proliferation (Fig. 3.2B).
Next, we investigated the importance of EGFR signaling in the proliferation of
the knock-down cells using inhibitory antibodies, and the small molecule EGFR inhibitor
gefitinib. Data shown in figure 3.3C shows that exposure of the parental cells to gefitinib
or EGFR blocking antibody for seven days inhibited cell growth by more than 80%
compared to growth in their normal cell culture media. Additionally, the residual cell
proliferation observed in the AREG knock-down cell lines was also inhibited by the
presence of the EGFR inhibitors. These results indicate that the proliferation observed in
the AREG knock-down cells is dependent on EGFR signaling. Furthermore, in one
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experimental group, an AREG neutralizing antibody was incubated with the AREG
knock-down and control cells for seven days (Fig. 3.3C). Unlike the EGFR antibody, the
AREG antibody did not further inhibit cell proliferation in the knock-down cells, while it
did reduce growth in control cells.
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Figure 3.3

Continued proliferation of AREG knock-down cells is EGFR dependent
(A) Western blot showing EGFR protein levels and (B) phosphorylation at specific
EGFR tyrosine residues during normal growth of MCF10A, SUM-149, SUM-149sh4,
SUM-149shPld, and SUM-149shNS cells. (C) SUM-149, SUM-149sh4, SUM-149shPld,
and SUM-149shNS cells were seeded at 1x104 cells per well. The first bar in each group
represents the number of cells on day one. The next four bars show the number of cells
after seven days in their normal growth media or with everyday exposure to 1 μg/ml
EGFR Ab, 0.5 μmol/L Iressa, or 1 μg/ml AREG Ab. Error bars represent the standard
deviation of three replicates in the experiment.
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Figure 3.4

EGFR localizes to the plasma membrane and cell-cell junctions after AREG knock-down
(A) EGFR localization in SUM-149, SUM-149sh4 +/- EGF and AREG, SUM-149shPld
+/- EGF and AREG, and SUM-149shNS. Cells were permeabilized, fixed, incubated with
EGFR Ab, a secondary alexa-fluor Ab, and mounted with DAPI prolong gold.
Representative confocal images are shown. Higher magnification of the cells is
represented in the panel on the left to show more detailed localization on the membrane
and at cell-cell junctions.
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There are seven known ligands that bind to and stimulate EGFR; EGF, AREG,
BTC, HB-EGF, TGF-, EREG, or EPGN. It was previously determined that SUM-149
cells synthesize EREG (Willmarth and Ethier, 2006).

To investigate the possible

expression of other EGFR ligands in SUM-149 AREG knock-down cells, real-time RTPCR analysis was performed. Data in figure 3.5A show that the expression of four of the
EGFR ligands was concomitantly down-regulated as a result of AREG knock-down.
However, two EGFR ligands, EGF and EPGN were not altered in their expression in the
AREG knock-down cells (Fig 3.5A). To determine if the observed down-regulation of
ligands in the AREG knock-down cells was due to reduced EGFR signaling, we analyzed
EGF-family ligand expression by real-time RT-PCR in SUM-149 cells before and after
treatment with gefitinib. After 24 hours of treatment with gefitinib, the same ligands that
were down-regulated in AREG knock-down cells were reduced in their expression
relative to non-treated SUM-149 cells (Fig. 3.5B). These data are consistent with the
hypothesis that decreased expression of AREG and other EGFR ligands in the AREG
knock-down cells is in response to the decrease in EGFR activation, and not to off target
effects of the shRNAs. Indeed, BLAST analysis of the AREG shRNA sequences did not
reveal any similarity to sequences present in other EGFR ligands.
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Figure 3.5

The role of EGF family ligands in growth of AREG knock-down cells
(A) Relative mRNA expression by real-time RT-PCR of AREG, EREG, EGF, TGF-a,
BTC, HB-EGF, and EPGN in the SUM-149, SUM-149sh4, SUM-149shPld, and SUM149shNS cells. (B) Relative mRNA expression by real-time RT-PCR of AREG, EREG,
TGF-a, BTC, HB-EGF, and EPGN in the SUM-149 and SUM-149 cells treated with 0.5
μmol/L Iressa for one or 24 hours.
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Since AREG knock down did not decrease expression of EGF or EPGN, we
investigated possible proliferative effects of endogenous EGF or EPGN on the growth of
knock-down and parental cells by performing growth assays using neutralizing antibodies
for each of the ligands. For seven days cells were treated with AREG, EGF, or EPGN
neutralizing antibodies or control antibodies, gefitinib, or an EGFR inhibitory antibody.
The experiment was performed using cells at different passage levels following AREG
knock-down. Figure 3.6A shows that at early passage after AREG knock-down (<p4)
EGF or EPGN neutralizing antibodies had no effect on growth of the knock-down cells.
When the growth assays were repeated with cells at a later passage after AREG knockdown (>p20), EGF and EPGN neutralizing antibodies reduced cell growth by about 20%
in the SUM-149sh4 and SUM-149shPld cells, while growth of SUM-149 and SUM149shNS cells was not affected (Fig. 3.6B). However, exposure to AREG neutralizing
antibodies also resulted in a decrease in growth of late passage SUM-149, SUM149shNS, and AREG knock-down cells. To confirm these results, real-time RT-PCR
analysis demonstrated that AREG mRNA expression in SUM-149sh4 and SUM149shPld cells at passage 18 after knock-down was only two-fold lower than control cells
as compared to 40-60-fold lower at early passage (Fig. 3.7). These data suggest that
AREG knock-down slows proliferation of SUM-149 cells, but as the cells are passaged
their growth rate increases through increased expression of AREG and other EGF-like
ligands.
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Figure 3.6
A..

B.

The role of EGF family ligands in growth of AREG knock-down cells
(C) Bars show growth of early passage cells (<p4) and (D) late passage cells after AREG
knock-down (>p18) Cells were seeded at 1x104 cells per well. The first bar in each group
represents the number of cells on day one. The next four bars show the number of cells
after seven days of growing in their normal growth media or with everyday exposure to
1ug/ml IgG mouse Ab, 1ug/ml IgG goat Ab, 1 μg/ml AREG Ab, 1 μg/ml EGF Ab,
1ug/ml EPGN Ab, 1ug/ml EGFR Ab or 0.5 μmol/L Iressa. Error bars represent the
standard deviation of three replicates in the experiment.
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Figure 3.7

A.

The role of EGF family ligands in growth of AREG knock-down cells
(E) Relative mRNA expression by real-time RT-PCR of AREG in late passage knockdown cells (>p18) with SUM-149 parental cells normalized to one.
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Knock-down of AREG Affects Cancer-associated Phenotypes
The ability to grow in soft agar is a hallmark of cancer transformation. Therefore,
we measured the soft agar colony forming ability of parental SUM-149 cells, SUM149sh4, SUM-149shPld, and SUM-149shNS cells. Figure 3.7A shows that SUM-149sh4
and SUM-149shPld cells formed 50% fewer colonies in soft agar after 3 weeks than
SUM-149 cells (Fig. 3.8A, 3.8C). However, given longer growth periods (four weeks),
AREG knock-down cells were able to produce a similar number of colonies as the SUM149 and SUM-149shNS controls (Fig. 3.8B, 3.8D), suggesting that the smaller number of
colonies observed at three weeks reflects the slower growth of the knock-down cells and
not their ability to survive under anchorage independent conditions.
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Figure 3.8

Effect of AREG knock-down on soft agar colony formation
The bars represent the number of colonies that grew in soft agar after three weeks (A) or
four weeks (B) of growth divided by the number of cells seeded (1x105). Cells were
counted with GelCount, automated mammalian cell counter. Error bars represent the
standard deviation of three replicates in the experiment. (C) Colonies formed after 3
weeks. (D) Colonies formed after 4 weeks.
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To determine whether AREG shRNA expression affects phenotypes of cancer
stem cells, we performed mammosphere colony forming assays. Cells were plated at
10,000 cells/well in ultra low attachment plates, cultured for one week, transferred to
standard tissue culture plates, and allowed to attach for two days before being stained and
counted. When the mammosphere assay was performed using the same growth factorfree medium used to maintain the control and knock-down cells, AREG knock-down
cells showed a decrease in mammosphere colony formation (Fig. 3.9). However, when
parental and knock-down cells were grown in stem cell medium which contains EGF,
there was no difference in the number of mammospheres that developed. We interpret
these results to indicate that the ability of SUM-149 cells to form mammospheres is not
influenced by the presence or absence of AREG. Previously, ALDH1 has been suggested
to be a marker of breast cancer stem cells and particularly in SUM-149 cells (CharafeJauffret et al., 2010; Charafe-Jauffret et al., 2009). To determine if the percentage of
ALDH1 positive cells was influenced by AREG knock-down, we performed Aldefluor
assays. Results of these experiments were consistent with the mammosphere assay and
indicated that AREG knock-down did not decrease the proportion of ALDH1 positive
SUM-149 cells (Data not shown).
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Figure 3.9
A.

Effect of AREG knock-down on mammosphere growth
(C) Cells were seeded at 1x104 cells in ultra-low attachment plates in mammosphere
media with (IHE) or with out (IH) 10 ng/ml of exogenous EGF. The bars represent the
number of spheres counted by visualization with a microscope. Error bars represent the
standard deviation of three replicates in the experiment.
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Next, we investigated the invasive capacity of the AREG knock-down cells in a
Matrigel invasion assay (BDbioscience). In these experiments, 25,000 SUM-149, SUM149sh4, SUM-149shPld, or SUM-149shNS cells were seeded on top of a Matrigel matrix
in Boyden chambers and incubated with their serum containing growth media below the
Matrigel for 24 hours. MCF10A cells were used as a negative control and showed little
invasion through the matrix, while, SUM-149 and the SUM-149shNS cells were highly
invasive. The data in figure 3.10 shows that both SUM-149 AREG knock-down cell
lines exhibited a dramatic decrease in the number of cells that invaded through the matrix
relative to the parental and control cells (Fig. 3.10A,B). Indeed, AREG knock-down
decreased the invasive capacity of the SUM-149 cells by greater than 75%. Taken
together, these results indicate that whereas AREG knock-down has a marginal effect on
SUM-149 cell soft-agar colony formation and no effect on the expression of stem cell
phenotypes, AREG knock-down has a dramatic effect on the motile and invasive capacity
of SUM-149 cells.
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Figure 3.10

AREG knock-down inhibits cellular invasion
(A) MCF10A, SUM-149, SUM-149sh4, SUM-149shPld, and SUM-149shNS cells were
seeded in serum free media on a Matrigel matrix and incubated at 37°C for 24 hours with
serum containing media as the chemoattractant. The bars represent the average number of
cells that invaded the matrix divided by the number of cells seeded (2.5x104 cells). Error
bars represent the standard deviation of three replicates in the experiment. (B) Photos
represent one field of view after staining invading cells.
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Effect of AREG knock-down on gene expression.
To examine the influence of AREG knock-down on the transcriptome of SUM149 cells, we performed DNA microarray analysis using Illumina micro-arrays. SUM149, SUM-149sh4, SUM-149shPld, and SUM-149shNS cells were grown to 80%
confluence and RNA was isolated one day after feeding. The RNA was reverse
transcribed and hybridized to the DNA array. All arrays were performed in triplicate.
Analysis of the microarray data indicated a statistically significant difference in
expression of 952 genes between SUM-149sh4 and SUM-149shNS cells. Of these, 659
genes were greater the 1.3 fold different between the two cell lines, and 381 genes
exhibited a greater than 1.5 fold difference. Ingenuity Pathway analysis (IPA) of the 952
gene set identified cell death (173 genes) and cellular movement (110 genes) as the top
two biological functions influenced by AREG knock-down.

With respect to cell

movement, AREG influenced expression of several genes that are part of canonical
pathways associated with cellular motility and invasion including: integrin-linked kinase
signaling, focal adhesion kinase signaling, caveolar mediated endocytosis signaling,
WNT signaling and Notch signaling (Table 3.1). Given our observation of the influence
of AREG knock-down on motility and invasion as shown in figure 3.9, the identification
of changes in specific genes associated with motility and invasion such as several
integrins, vimentin, and MMPs (Table 3.1) were consistent with those experimental
observations. Up-regulation of two specific genes, DKK1 and RHOB, which have been
implicated in cancer cell motility and invasion (Jiang et al., 2004; Pukrop et al., 2006)
were chosen for validation experiments. Data in figure 3.11 shows that changes in
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expression level of each gene by real-time RT-PCR were consistent with the micro-array
results, and western blot analysis demonstrated an increase in expression of RHOB
associated with AREG knock-down (Fig. 3.11A,B,C). In several studies, DKK1 and
RHOB have been implicated as negative regulators of cellular motility (Jiang et al., 2004;
Pukrop et al., 2006). The expression of RHOB and DKK1 was low in SUM-149 cells
and was increased approximately 10-fold in the AREG knock-down cells (Fig 3.11B,C).
Thus, results of microarray analysis of SUM-149sh4 and SUM-149shNS cells are
consistent with the biological experiments with respect to motility and invasion, and also
point to other important pathways that could be regulated by AREG in these cells.

85

Table 3.1

Summary of genes regulated by AREG knock-down in SUM-149 cells
Six signaling pathways associated with cell motility and invasion are listed in bold. The
top three genes up and down regulated in each pathway are listed beneath each signaling
pathway as determined by Ingenuity Pathways Analysis.

86

Figure 3.11

Validation of increased expression of RHOB and DKK1 in AREG knock-down cells
(A) Western blot showing RhoB protein expression in parental and knock-down cells. Actin is used as a loading control. Relative mRNA expression by real-time RT-PCR of
(B) RHOB and (C) DKK1 mRNA expression with SUM-149 or SUM-149shNS parental
cells normalized to one.
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3.3 Discussion
Over expression of EGFR correlates with advanced stage and a poor prognosis in
many types of cancer, including breast cancer (Salomon et al., 1995a). Neal et. al. (Neal
et al., 1985) found EGFR expression correlates with poor differentiation and invasion in
transitional cell carcinoma of the bladder. Additionally, over expression of EGFR is
accompanied by autocrine regulation of its stimulating ligands (Voldborg et al., 1997).
Our lab has shown that AREG promotes proliferation of SUM-149 breast cancer cells
through the expression of an AREG/EGFR autocrine loop (Willmarth and Ethier, 2006).
The present work examined transformed phenotypes in SUM-149 cells following knockdown of AREG using lentiviral AREG shRNAs. We found that AREG knock-down
failed to completely inhibit cell proliferation, although it did slow the growth-rate of
cells. In addition, knock-down did not significantly inhibit the cells’ ability to form
colonies in soft agar nor did it affect the expression of stem-cell phenotypes as
determined by mammosphere colony formation and Aldefluor staining. However cells
with AREG knock-down exhibited a dramatic decrease in their invasive capability.
Moreover, microarray data were consistent with this observation and identified a number
of genes associated with invasive and motile phenotypes that were altered in expression
by AREG knock-down.
The observation that dramatic levels of AREG knock-down did not completely
block growth of SUM-149 cells, was unexpected.

These knock-down cells, while

expressing undetectable levels of AREG by ELISA and western blot, continued to
express tyrosine phosphorylated EGFR. The increase in steady-state levels of EGFR
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protein in the knock-down cells, as detected by western blot, is consistent with reduced
EGFR activity in these cells. Further, EGFR remained localized to the cell surface in the
knock-down cells (Fig. 3.11). However, EGFR remained active and was responsible for
the continued proliferation of the knock-down cells as exposure to either EGFR
neutralizing antibodies or small molecule inhibitors completed the inhibition of growth of
the knock-down cells.
We observed that AREG levels steadily increased in the knock-down cells with
passage after infection with lentiviral AREG shRNA vectors. This finding, coupled with
the residual proliferation and EGFR activation in the knock-down cells suggests that
small sub-populations of cells were present that continued to express low levels of
AREG, and that these cells increased in proportion with each passage. Interestingly, this
low-level AREG mediated cell growth was not affected by AREG neutralizing
antibodies.

If this interpretation is correct, it would explain the continued EGFR

activation observed in the population of cells that were responding to paracrine growth
factors secreted by this sub-population. This interpretation also has implications for the
ability of breast cancer cells to respond to very low levels of EGFR ligands, particularly
when EGFR accumulates on the cell surface.
We were surprised to find that knock-down of AREG resulted in concomitant
decreases in expression of other EGFR ligands, Previously, we showed that AREG
mRNA expression in SUM-149 cells is regulated by EGFR activation (Willmarth and
Ethier, 2006). Results presented here extend that finding and demonstrate that reduced
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EGFR activation, whether via AREG knock-down or EGFR inhibition, results in
decreased transcription of several EGFR ligands, not just AREG.
Despite the inability to completely block proliferation of SUM-149 cells
following AREG knock-down, we did find that these cells had dramatically reduced their
invasive capacity.

Numerous studies have shown that EGF stimulation of EGFR

promotes cell invasion and motility in various cancers including glioblastoma, squamous
cell carcinoma, bladder, gastric, renal, prostate, and breast cancer (Libermann et al.,
1984; Neal et al., 1985; Ozawa et al., 1987; Price et al., 1996; Schlegel et al., 1994; Toi et
al., 1990; Tokunaga et al., 1995; Turner et al., 1996). On the contrary, there have been
few studies reporting AREG promotion of invasion. Invasion associated with AREG has
been described in vitro in breast and head and neck cancers. In two different studies,
squamous cell carcinomas have been shown to secrete AREG in response to G proteincoupled receptor (GPCR) ligand stimulation resulting in cell proliferation, motility, and
invasion (Gschwind et al., 2003; Zhang et al., 2006).
In normal epithelial tissue, AREG is expressed during development of the
embryonic lung (Schuger et al., 1996) and in the pubertal mammary gland during ductal
morphogenesis and terminal end bud (TEB) formation (Ciarloni et al., 2007; Luetteke et
al., 1999). EGFR and AREG interactions occur in the stroma thereby stimulating the
proliferation of nearby epithelial cells in the ducts and TEBs. Similarly, embryonic lung
branching of the epithelial trees depends on the presence of AREG as well as the
presence of the extracellular matrix (ECM) (Schuger et al., 1996). The important role of
AREG/EGFR interactions in tissue development and morphogenesis is consistent with
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the pathological role of AREG in mediating motility and invasion when inappropriately
expressed in cancer cells.
Mechanisms proposed for AREG/EGFR induced cellular invasion focus on the
altered expression of matrix metalloproteases (MMPs). These proteases play a role in
embryonic development and growth, while in cancer they function in breaking down the
basement membrane barrier. In metastatic breast cancer cells (SKBR-3), an increase in
MMP-9 expression modulates AREG promotion of invasion (Kondapaka et al., 1997).
Additionally, inhibition of AREG by anti-sense cDNA in NS2T2A1 mouse mammary
tumor cells inhibited MMP-9 expression (Ma et al., 2010). Microarray data comparing
gene expression in AREG knock-down cells to cells infected with the non-silencing
control are consistent with the report of Ma et. al., in that we also found MMP-9
expression was decreased in SUM-149sh4 knock-down cells (Table1).

Our gene

expression profiling data also indicated a role for AREG in the regulation of expression
of other genes that play a role in invasion such as RHOB and DKK1. Rho GTPase’s,
regulate cytosekeltal rearrangements during cell invasion and motility in inflammatory
breast cancer (IBC) cells (Lin and van Golen, 2004), and RhoB expression has been
shown to be dramatically reduced as tumors become more aggressive (Adnane et al.,
2002; Forget et al., 2002; Mazieres et al., 2004). DKK1, which acts as a negative
regulator or WNT signaling, has also been implicated in regulating the invasive
phenotype (Pukrop et al., 2006). Thus, our observation of dramatic up-regulation of
DKK1 in AREG knock-down cells is consistent with a role of WNT signaling in
modulating the invasive phenotype.
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In summary, our results with AREG- knock-down versions of SUM-149 cells not
only point to roles of the autocrine ligand in maintaining proliferation of the cells in an
autocrine manner, but provide further support for the hypothesis that AREG activated
EGFR is a major driver of invasion in breast cancer cells. Furthermore, our results
suggest that the invasive phenotype is a result of the altered signaling that occurs in cell
surface localized EGFR, which occurs as a direct result of AREG-EGFR interaction, and
is in contrast to what occurs with other EGFR ligands, particularly EGF, which drives
internalization and degradation of the receptor. It would be constructive to test our
findings in additional cell lines where the cells rely on AREG as the SUM-149 cells do
and in an experimental in vivo model.

Further work is required to understand the

mechanistic basis for EGFR stability and cell surface localization of AREG activated
EGFR.
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CHAPTER 4
GENOME-WIDE ANALYSIS OF GENE EXPRESSION REGULATED
BY AREG IN NORMAL AND BREAST CANCER CELLS

4.1 Introduction
SUM-149 cells expressing shRNA constructs specific to AREG demonstrated a
decrease in cell proliferation, a decrease in cellular invasion, and an increase in the
expression of cell surface localized EGFR protein. These results led us to investigate
differences occurring in the biology of the cell. By microarray analysis we measured
AREG’s involvement in various cellular events and processes. We isolated RNA from:
SUM-149, SUM-149sh4, SUM-149shPld, and SUM-149shNS cells, reverse transcribed
the RNA to cDNA and hybridized the cDNA to an Illumina array (described in Chapter
3).
To address further the biological the role of AREG, we cultured MCF10A cells
either with or without EGF or in the presence or absence of exogenous AREG. MCF10A
cells are spontaneously immortalized cells derived from mammary epithelial cells (Soule
et al., 1990). MCF10A cells were continuously grown in serum free media supplemented
with 10ng/ml of EGF (MCF10A) or 20ng/ml of AREG (MCF10A+AREG).
Additionally, we withdrew EGF or AREG for 24 hours from MCF10A and
MCF10A+AREG cells, respectively.

RNA from MCF10A+/-EGF and MCF10A+/-

AREG was isolated; cDNA was synthesized and hybridized to an Illumina array. By
Ingenuity Pathway Analysis (IPA) we found AREG expression to be associated with
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NOTCH signaling in the context of cancer cells only, and with Wnt signaling in both
normal and cancer cells. Wnt and NOTCH signaling pathways function in stem cell
biology and play major roles in mammary gland development and tumorigenesis (Collu
and Brennan, 2007; Molofsky et al., 2004).

Wnt signaling alone can cause

tumorigenesis; however, recently it has been hypothesized that there is cross talk between
two pathways promoting tumorgenesis (Ayyanan et al., 2006).
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4.2 Results
Venn diagrams
We

performed

microarray

analysis

with

three

experimental

groups,

MCF10A+EGF, MCF10A+AREG and SUM-149 cells. MCF10A cells withdrawn of
AREG for 24 hours were compared to MCF10A cells growing in the presence of AREG,
and, MCF10A cells withdrawn of EGF for 24 hours were compared to MCF10A cells
growing in the presence of EGF. SUM-149shNS cells were compared to SUM-149sh4
cells. Figure 4.1 shows a Venn diagram representing the number of genes changed in
each gene list and the number of genes that overlap in the three groups as determined by
T-Test and RankProd statistical analysis where p < 0.05.
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Figure 4.1

Venn Diagram
(A) Venn diagram of genes differentially expressed by MCF10A+/- EGF, MCF10A+/AREG and SUM-149 cells. Expression based on T-test and RankProd statistical analysis.
Biological processes and gene lists are represented in Tables (4.2, 4.4, 4.6, and 4.8)
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The molecular profile of MCF10A cells regulated by AREG differs from
MCF10A cells regulated by EGF. However, there are 725 genes that are commonly
regulated by both growth factors (Figure 4.1). The main cellular process regulated by
both EGF and AREG in MCF10A cells are: cell cycle, followed by cellular assembly and
organization, and DNA replication, recombination, repair (Table 4.1). The top canonical
pathways and associated genes regulated by EGF and AREG are listed in Table 4.2. As
expected, genes and pathways associated with cell division and thus tissue growth were
the most significantly altered by the removal of both EGF and AREG.

Cyclins,

transcription factors, and cell cycle checkpoint genes were the most significantly affected
by AREG and EGF (Table 4.2).
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Table 4.1
Molecular and Cellular Functions
Regulated by EGF and AREG in MCF10A cells
Name

p-value

# of molecules

Cell Cycle

1.59 x 10-31

129

Cellular Assembly and Organization

2.21 x 10-13

50

DNA Replication, Recombination, Repair

2.21 x 10-13

111

Cellular Growth and Proliferation

1.03 x10-9

164

Cellular Movement

2.01 x10-9

82

Molecular and Cellular Functions Regulated by EGF and AREG in MCF10A cells
Listed are the five most significantly altered cellular functions, the number of genes
expressed in each function, and the statistical significance are listed
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Table 4.2

Summary of genes in specific canonical pathways regulated by EGF and AREG in
MCF10A cells
Five signaling pathways associated with cell cycle control and mitosis are listed in bold.
The top genes up and down regulated in each pathway are listed beneath each signaling
pathway as determined by IPA.
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Comparison of MCF10A+AREG cells to MCF10A cells in the absence of AREG
for 24 hours resulted in a list of 1269 statistically significant differentially regulated
genes (Figure 4.1). These genes are regulated by AREG in the MCF10A model. 465 of
these genes are regulated by AREG (Figure 4.1, red). The top cell function regulated by
AREG in MCF10A-AREG cells versus MCF10A+AREG gene lists, based on statistics,
is cell death followed by cellular movement and cell cycle (Table 4.3). Table 4.3 lists the
genes differentially regulated by AREG in some of the statistically significant canonical
pathways. Among these pathways are: NRF-2-mediated Oxidative Stress Response,
Interferon Signaling, Glutathione Metabolism, Xenobiotic Metabolism Signaling, and
Wnt signaling. Genes up and down regulated in the top canonical pathways are listed in
Table 4.4. The pathways and genes altered by AREG in MCF10A cells are associated
with oxidative stress. Reactive oxidative species (ROS) can cause a significant damage
to molecules and cell structures in the cell. NRF-2 signaling induces the transcription of
genes influencing oxidative stress, thereby defending the body against oxidative stress
(Sykiotis, Science, 2010). Xenobiotics are sources of ROS and glutathione transferases
are enzymes that can alleviate/detoxify the ROS stress response. AREG in these cells
induces the expression of glutathione signaling moleules to remove the harmful effects of
the xenobiotic signaling molecules. In addition to altered ROS signaling Wnt signaling is
influenced by the AREG in MCF10A cells.
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Table 4.3
Molecular and Cellular Functions
Regulated by AREG in MCF10A cells
Name

p-value

# of molecules

Cell Death

1.26 x 10-5

79

Cellular Movement

4.20 x 10-5

49

Cell Cycle

1.71 x 10-4

37

Free Radical Transport

2.09 x10-4

11

Molecular Transport

2.09 x10-4

15

Molecular and Cellular Functions Regulated by AREG in MCF10A cells
Listed are the five most significantly altered cellular functions, the number of genes
expressed in each function, and the statistical significance are listed
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Table 4.4

Summary of genes in specific canonical pathways regulated by AREG in MCF10A cells
Six signaling pathways associated with oxidative stress and ROS signaling are listed in
bold. The top genes up and down regulated in each pathway are listed beneath each
signaling pathway as determined by IPA.
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79 genes were regulated by AREG in both normal (MCF10A) and cancer (SUM149) cells (Figure 4.1, purple).

Cell-to-cell signaling and interaction was the most

significantly altered (Table 4.5). In addition, cell movement was a highly significant
process that was regulated by AREG in both MCF10A and SUM-149 cells. These
analyses corroborate the findings from chapter 3 showing AREG promotes cell motility
and invasion in SUM-149 cells. Table 4.6 lists the top canonical pathways and the genes
commonly regulated by AREG in SUM-149 and MCF10A cells. These pathways include
Clatherin mediated endocytosis and Wnt Signaling; however, the degree of change is
greater in the SUM-149 cells than in the MCF10A cells. Genes in these pathways
include the integrins, SFRP1, and a frizzled receptor (Table 4.6).
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Table 4.5
Molecular and Cellular Functions
Regulated by AREG in MCF10A and SUM-149 cells
Name

p-value

# of molecules

Cell-to-Cell Signaling and Interaction

2.78 x 10-7

17

Cell Death

5.83 x 10-6

20

Cellular Movement

5.92 x 10-6

14

Cell Cycle

7.54 x10-5

12

Cell Growth and proliferation

1.17 x10-4

23

Molecular and Cellular Functions Regulated by AREG in MCF10A and SUM-149 cells
Listed are the five most significantly altered cellular functions, the number of genes
expressed in each function, and the statistical significance are listed
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Table 4.6

Summary of genes in specific canonical pathways regulated by AREG in MCF10A and
SUM-149 cells
Five signaling pathways associated with endocytosis and Wnt signaling are listed in bold.
The top genes up and down regulated in each pathway are listed beneath each signaling
pathway as determined by IPA.
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Gene regulation by AREG plays a distinct role in SUM-149 breast cancer cells.
952 genes were altered in their expression after shRNA knock-down of AREG compared
to a non-silencing vector (Figure 4.1). The list of genes produced were analyzed by IPA
in chapter 3. Table 3.1 (chapter 3) lists the top five signaling pathways altered as a result
of AREG knock-down and the top 3 genes up- and down-regulated relative to each
signaling pathway.
Of the 952 genes, 549 genes were regulated by AREG only in the SUM-149
breast cancer cells and not the MCF10A cells, 140 genes were regulated by both EGF and
AREG in SUM-149 and MCF10A+/-EGF cells, 184 genes were regulated by
MCF10A+/-AREG, SUM-149, and MCF10A+/-EGF, and 79 genes were regulated by
AREG in SUM-149 and MCF10A+/-AREG cells (Figure 4.1). In the 549 gene list
produced the most significant cellular functions affected were cellular movement, cell
death, and cell cycle (Table 4.7). The top genes either up- or down-regulated by AREG
in SUM-149 cells are listed under each canonical pathway in Table 4.8. The most
significantly altered pathway was Agrin Interactions at Neuromuscular Junction. Genes
altered in this pathway are predominantly associated with cellular motility, such as
ITGB2, CTTN, and ITGA6.

The observed decrease in cell invasion and motility

following AREG knock-down in SUM-149 cells correlates with the gene lists created by
IPA.
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Table 4.7
Molecular and Cellular Functions
Regulated by AREG in SUM-149 cells
Name

p-value

# of molecules

Cellular Movement

1.88 x 10-5

53

Cell Death

6.79 x 10-5

84

Cell Cycle

5.65 x 10-4

24

Cellular Growth and Proliferation

6.05 x10-4

89

Cell-to-Cell Signaling and Interaction

7.34 x10-4

41

Molecular and Cellular Functions Regulated by AREG in SUM-149 cells
Listed are the five most significantly altered cellular functions, the number of genes
expressed in each function, and the statistical significance are listed
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Table 4.8

Summary of genes in specific canonical pathways regulated by AREG in SUM-149 cells
Five signaling pathways associated with cell motility, invasion, and NOTCH signaling
are listed in bold. The top genes up and down regulated in each pathway are listed
beneath each signaling pathway as determined by IPA.
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Only in SUM-149 cells did we observe altered NOTCH signaling in response to
AREG. NOTCH signaling regulates cell communication in embryonic and adult
development. Furthermore we observed the Wnt signaling pathway to be regulated by
AREG in SUM-149 cells. Based on the finding that NOTCH signaling was only affected
in the SUM-149 cell model and not the MCF10A cell model, we chose to validate
molecules in this signaling pathway. Figure 4.2 depicts the NOTCH signaling pathway
and the genes altered by AREG in SUM-149sh4 versus SUM-149shNS cells. After
AREG knock-down we observed a decrease in gene expression of Contactin1 (CNTN1),
a cell adhesion molecule that enhances NOTCH signaling and plays a role in tumor
invasion and motility, present on the extracellular surface of a cell. CBF1, Suppressor of
Hairless, LAG-1 (CSL), a well characterized transcription repressor, hairy/enhancer of
split (E(spI))-related family of transcription factors (HES genes 1,5, and 7, and HEY1),
transcriptional targets of CSL, were also down-regulated after AREG knock-down
(Purow et al., 2005). The HEY/HES family are NOTCH target genes that counteract or
block differentiation.

They negatively regulate the expression and/or function of

transcription factors influencing the determination of cell lineage (Meier-Stiegen et al.,
2010; Schwanbeck et al., 2010). We confirmed the down-regulation of CNTN1, HES7,
and HEY1 by real-time RT-PCR (Figure 4.3). HES7 and HEY1 in Hodgkin lymphoma
cells have been shown to be over expressed as a result of aberrant NOTCH signaling
(Kochert et al., 2010).
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Figure 4.2

NOTCH Signaling Pathway
Genes in the NOTCH signaling pathways that are regulated by AREG only in the SUM149 cells. Green indicates the gene is down-regulated and red indicates the gene is upregulated.
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Figure 4.3
CNTN1
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Validation of decreased expression of CNTN1, HEY1, and HES7 in AREG knock-down
cells
(A) Relative mRNA expression by real-time RT-PCR of CNTN1, HEY1, and HES7
mRNA expression in AREG knock-down cells with SUM-149 parental cells normalized
to one.
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4.3 Discussion
By utilizing IPA we were able to identify signaling pathways that were altered by
the expression profiles in figure 4.1. Wnt and NOTCH signaling pathways arose as
pathways that were affected in the expression profiles of SUM-149 and MCF10A+/AREG cells.

A recent study, aimed at identifying priming factors contributing to

progression from lung dysplasia to cancer identified an up-regulation of AREG and
notably, NOTCH and Wnt signaling cascades (Rohrbeck and Borlak, 2009).

The

identification of these pathways in our system encourages further investigation.
NOTCH signaling occurs when the extracellular domain of the NOTCH receptor
on one cell binds to the extracellular domain of a NOTCH ligand on a neighboring cell;
therefore, NOTCH signaling requires cell-cell contacts. Interestingly NOTCH signaling
was altered by AREG only in the SUM-149 cells (Table 4.7 and 4.8, Fig 4.2 and 4.3).
The MCF10A+/-AREG gene profiles did not reflect any changes in NOTCH signaling.
This suggests that activation of the NOTCH signaling cascade is contextually dependent,
as we only observed its activation in the cancer cell model.
In addition to NOTCH signaling, genes commonly regulated by SUM-149sh4
versus shNS and MCF10A+/-AREG cells influenced the Wnt signaling pathway (Table
4.5 and 4.6, Fig. 4.4). Wnt signaling influences stem cell self-renewal in a variety of
epithelial cells (Reya et al., 2001). We observed changes in the Wnt pathway in all of the
gene lists, however the change in gene regulation varied. In the Wnt pathway, the level
of change in expression of the genes increased in the AREG model compared to the EGF
model. Similarly, genes regulated in the SUM-149 cells, especially DKK1, expressed
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higher levels of differential expression than the MCF10A+/-AREG gene expression
profiles. DKK1, SFRP1, and Wnt were down-regulated in the absence of AREG. The
array data was confirmed by analyzing DKK1 mRNA expression by real-time RT-PCR
(Fig. 3.10). DKK1 expression was down-regulated in all three cell models, but the
expression was down-regulated by approximately one tenth of the expression levels
observed when regulated by AREG.
A summary of the flow of genes expression, molecular functions, and signaling
pathways are shown in a flow chart in figure 4.5.

In cancer cells, the change in

expression of negative Wnt regulators is dramatically increased. This suggests that Wnt
signaling, in addition to NOTCH signaling, is context dependent.
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Figure 4.4

Wnt Signaling Pathway
Genes in the Wnt signaling pathways are regulated by AREG in both MCF10A and
SUM-149 cells. Green indicates the gene is down-regulated and red indicates the gene is
up-regulated. The intensity of the red or green indicates the level of up- or downregulation
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Figure 4.5
MCF10A+/-AREG ---- MCF10A+/-EGF
Molecular Functions: Cell cycle, cellular growth and proliferation
Signaling Pathways: low level of  in negative Wnt Regulator DKK1, regulation of cell cycle checkpoint genes

MCF10A+/-AREG

MCF10A+/-EGF

Molecular Functions: Cell death and movement

Molecular Functions: Cell cycle, cell checkpoints

Signaling Pathways: Increased level of  in Wnt negative regulator
SFRP1, but not DKK1, NRF-2-mediated oxidative stress

Signaling Pathways: low levels of  in Wnt negative regulator DKK,
but not SFRP1

SUM-149+/-shAREG --- MCF10A+/-AREG
Molecular Functions: Cell-to-cell signaling, cell movement
Signaling Pathways: low level of  in negative Wnt Regulator DKK1, regulation of clatherin mediated
endocytosis genes

SUM-149+/-shAREG
Molecular Functions: Cell movement, cell death
Signaling Pathways: high levels of  in negative Wnt Regulators DKK1 and SFRP1, regulation of NOTCH
signaling

Change of Flow in Molecular Function and Signaling Pathway Regulation
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CHAPTER 5
CONCLUSIONS AND FUTURE DIRECTIONS

SUM-149 is an aggressive, highly transformed, primary, triple negative,
inflammatory breast cancer cell line.

These cells are EGF-independent for growth,

motile, and highly invasive (Hoffmeyer et al., 2005; Jia et al., 2004; Willmarth and
Ethier, 2006). They express relatively high levels of constitutively active EGFR and are
dependent on EGFR for growth (Rao et al., 2000). In order to understand the EGFindependent phenotype and the constitutive activation of EGFR, genes that promoted
EGF-independent growth were isolated from MCF10A cells infected with a cDNA
library from SUM-149 cells. From these experiments AREG was identified as the gene
mediating EGF-independent growth in SUM-149 cells (Berquin et al., 2005).
The discovery of AREG expression in SUM-149 cells and the identification of
AREG and EGFR co-over expression in inflammatory breast cancer lead to our focus on
AREG (LeJeune et al., 1993; Ma et al., 2001). AREG is over expressed at the protein
and mRNA level.

Inhibition of the ligand with a neutralizing AREG antibody,

preventing ligand binding to EGFR, inhibited cell proliferation suggesting that AREG is
the autocrine factor driving the EGF-independent phenotype (Willmarth and Ethier,
2006). In addition, we observed that the synthesis of AREG is also regulated by EGFR
signaling. It was the results from these experiments that led us to the identification of an
AREG/EGFR autocrine loop in SUM-149 cells. The AREG/EGFR autocrine loop, in
addition to regulating cell proliferation, was also found to regulate the localization of

116

EGFR and the cellular motility and invasiveness of SUM-149 cells (Willmarth and
Ethier, 2006). Stemming from the findings of Pan et. al. that SUM-149 cells express
constitutively active NF-B, our lab discovered a NF-B/IL- feedback loop
interconnected the AREG/EGFR autocrine loop that influences that proliferative,
migratory, and invasive capacity of the SUM-149 cells (Pan et al., 2003; Streicher et al.,
2007).
These previous experiments led us to knock-down the expression of AREG. Our
initial hypothesis, based on the observation that an AREG/EGFR autocrine loop functions
in regulating SUM-149 cell proliferation, was that AREG knock-down would inhibit cell
proliferation. We found that AREG knock-down, in a polyclonal population, allowed for
cells to continue proliferating albeit at a slower rate. However, as cells were passaged the
levels of AREG expression increased.

In addition, the EGFR levels increased and

localized to the cell membrane. This suggested that breast cancer cells are able to
respond to very low levels of EGFR ligands, particularly when EGFR accumulates on the
cell surface.
Recently, clones were derived from SUM-149sh4 cells. By real-time RT-PCR,
clonal derivative SUM-149sh4-c1 showed the greatest knock-down of AREG compared
to the SUM-149 parental and SUM-149shNS controls while c5 had the highest levels of
AREG mRNA and protein expression (data not shown). Some cells growing in the
polyclonal population are producing AREG. This suggests that AREG produced in these
cells supports the growth of the entire population by paracrine signaling mechanisms and
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that these AREG expressing cells are slowly taking over the culture, hence why we
observe increased AREG expression as the cells are passaged.
Given that SUM-149 cells are capable of growing in serum free conditions, SUM149sh4 clonal derivatives were switched from 5% serum to serum free media. SUM149sh4-c1 grows slower than the polyclonal SUM-149sh4 cells while SUM-149sh4-c4
and c6 do not proliferate at all and show signs of mitotic catastrophe and apoptosis in
serum free conditions (data not shown). It is now our understanding that there may be
serum factors that help to promote proliferation of the SUM-149sh4 population. To truly
understand AREG knock-down we need to continue our studies using the clonal
derivatives grown in serum free media. Future studies should be directed at studying
AREG knock-down in other cell lines over expressing AREG, such as the ovarian cancer
cell line, KCI-OV1. In addition, it would be valuable to study the invasive capacity and
rate of proliferation of the knock-down cells in an in vivo model.
Our findings presented in this dissertation highlight the pathological role of
AREG in tumor progression. In the past, EGFR’s promotion of disease progression has
been associated with EGFR when it is either amplified or mutated. In our cell model,
AREG drives EGFR accumulation to the cell membrane in the absence of an EGFR
mutation or amplification. Moreover, our findings suggest that cell surface EGFR when
stimulated by AREG, as opposed to EGF, has a pathological role in promoting tumor
invasion.
Previous studies support our finding of AREG’s role in enhancing cellular
invasion (Gschwind et al., 2003; Zhang et al., 2004). The mechanism(s) by which AREG
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can promote invasion is still unclear. The genetic profiles we have obtained in our
microarray studies lead us to cell signaling pathways altered in the absence of AREG for
further investigation. For example, Wnt signaling is one signaling pathway regulated
only by AREG and not by EGF in either normal (MCF10A) and cancer (SUM-149) cells.
Wnt and NOTCH are two signaling pathways, among others like hedgehog, that
regulate stem-cell self renewal (Molofsky et al., 2004). Stem cell self-renewal is
regulated by the coordination of multiple signaling pathways (Molofsky et al., 2004).
Wnt signaling promotes the proliferation and maintenance of stem cells by either
canonical (with -catenin) or non-canonical signaling (Cobas et al., 2004; Reya and
Clevers, 2005). Expression of DKK1 and Secreted frizzled-related protein1 (SFRP1),
genes involved in the Wnt pathway, inhibit Wnt signaling and, therefore, the proliferation
of stem cells (Mao et al., 2002). Removal of either EGF or AREG from normal epithelial
cells slightly up-regulates DKK1, but not secreted frizzled receptor protein 1 (SFRP1),
and knock-down of AREG in SUM-149 breast cancer cells dramatically up-regulates
DKK1 and SRFP1. These data suggest that SUM-149 cells with AREG/EGFR signaling
induces Wnt signaling, which promotes stem cell self-renewal, perhaps in concert with
NOTCH signaling.

Further experiments should analyze the involvement of Wnt

signaling and invasion in cells that are responding to an AREG/EGFR autocrine loop
In addition to Wnt signaling, gene lists and signaling pathways derived from
microarray data comparing the SUM-149 AREG knock-down to the shNS control shined
a light on NOTCH signaling. NOTCH signaling has been suggested to act coordinately
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with Wnt signaling to regulate stem cell self-renewal. Interestingly, NOTCH signaling
was observed only in the cancer cells and not in the MCF10A cell model.
NOTCH signaling, depending on the context, can inhibit or promote stem-cell
renewal (Henrique et al., 1997; Hitoshi et al., 2002). In addition, NOTCH signaling has
been observed to promote differentiation (Morrison et al., 2000). Our data suggest that
AREG/EGFR signaling is playing a role in the stem cell biology of breast cancer cells by
shifting the probability of a symmetric division of two stem cells, therefore maintaining
the stem cell population. The down-regulation of the HES/HEY family of stem cell
differentiation repressors after AREG knock-down indicates that in the presence of
AREG/EGFR signaling stem cells continue to divide and produce more stem cells. This
results in expansion of a self-renewing stem cell population resulting in tumorigenesis.
Further investigation of context dependent NOTCH signaling in SUM-149 cells as
regulated by AREG would be of great interest.
Our studies translate to the clinic, as AREG is a potential bio-marker for
aggressive and invasive disease. After EGFR inhibition, the AREG/EGFR axis makes
cells more sensitive to radiation (Rao et al., 2000). Additionally, AREG/EGFR sensitizes
patients to treatment with cetuximab (Khambata-Ford et al., 2007). Our studies suggest
that AREG/EGFR promotes an aggressive and highly transformed form of breast cancer.
Recently, high concentrations of AREG in the serum have been suggestive of better
disease-specific survival when non-small cell lung patients were treated with EGFR
tyrosine kinase inhibitors (Vollebergh et al., 2010). Therefore, patients could benefit
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from being screened for the serum levels of AREG and then be given a more appropriate
treatment regime.
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We have previously shown that SUM-149 human breast cancer cells require an
AREG/EGFR autocrine loop for cell proliferation. We also demonstrated that AREG can
increase EGFR stability and promote EGFR localization to the plasma membrane. In the
presented dissertation we successfully knocked-down AREG expression in SUM-149
cells by lenti-viral infection of AREG shRNA. In the absence of AREG expression,
SUM-149 cell growth was slowed, but not completely inhibited. Furthermore, cells
infected with AREG shRNA constructs showed an increase in EGFR protein expression
by western blot. Immunofluorescence and confocal microscopy showed that following
AREG knock-down, EGFR continued to localize to the cell surface. Soft agar assays
demonstrated that AREG knock-down cells retain anchorage-independent growth
capacity. Additionally mammosphere forming assays and Adefluor staining analysis
showed that knock-down of AREG expression did not affect the expression of stem cell
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phenotypes. However, following AREG knock-down, SUM-149 cells demonstrated a
dramatic decrease in their ability to invade a Matrigel matrix. Consistent with this
observation, microarray analysis comparing cells infected with a non-silencing vector to
the AREG knock-down cells, identified genes associated with the invasive phenotype
such as RHOB and DKK1, and networks associated with cell motility such as integrinlinked kinase signaling, and focal adhesion kinase signaling. AREG was also found to
modulate WNT and Notch signaling in SUM-149 cells. In an additional microarray
study, changes in gene expression were analyzed from cDNA transcribed from RNA
isolated from MCF10A cells growing in the presence of AREG or EGF and after 24
hours withdrawl of the respective ligand. Genes regulating WNT signaling, but not
NOTCH signaling, were altered in the MCF10A cells.

Thus, the pathway that

AREG/EGFR signaling effects is contextually dependent on the cell type that it is
functioning in. We conclude that AREG functions in regulating the invasive phenotype,
and we propose that this regulation may be through altered signaling that occurs when
AREG activates plasma membrane localized EGFR.
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